Phenylpyrazole derivatives

ABSTRACT

The present invention provides a prophylactic or therapeutic agent for dementia, Alzheimer&#39;s disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases. 
     A phenylpyrazole derivative represented by formula (1) or a pharmaceutically acceptable salt thereof: 
     
       
         
         
             
             
         
       
     
     {wherein
         R 1  and R 2 , which may be the same or different, each represent C 1 -C 6  alkyl or C 3 -C 8  cycloalkyl, or   R 1  and R 2  are attached to each other together with their adjacent nitrogen atom to form a 4- to 7-membered saturated heterocyclic ring (wherein said saturated heterocyclic ring may be substituted with halogen or C 1 -C 6  alkyl),   n represents an integer of 0 to 2,   T represents a hydrogen atom, halogen or C 1 -C 6  alkyl, and   R represents formula (I):       

     
       
         
         
             
             
         
       
     
     or the like}.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of U.S. patent applicationSer. No. 12/741,754, filed May 6, 2010 (now allowed), which is aNational Stage of International Application No. PCT/JP2008/070712 filedNov. 13, 2008, claiming priorities based on Japanese Patent ApplicationNos. 2007-294040 filed Nov. 13, 2007, and 2008-153736 filed Jun. 12,2008, the contents of all of which are incorporated herein by referencein their entirety.

BACKGROUND ART

Histamine is usually stored within intracellular granules in mast cells,lung, liver and gastric mucosa, etc. In response to external stimulisuch as antigen binding to cell surface antibody, histamine is releasedinto the extracellular environment. For example, when mast cells arestimulated by an antigen entering from outside, histamine is releasedfrom the mast cells and stimulates histamine H1 (H1) receptors locatedon blood vessels or smooth muscle to cause allergic reactions. Likewise,histamine released from ECL cells (enterochromaffin-like cells) on thegastric mucosa stimulates histamine H2 (H2) receptors on the parietalcells to promote gastric acid secretion. Based on these facts, H1 and H2receptor antagonists have been developed as therapeutic agents forallergic diseases and gastric ulcer, respectively, both of which are nowused widely as medicaments.

Further, it has been elucidated that histamine serves as aneurotransmitter and acts on the third histamine receptor (histamine H3(H3) receptor) located in central and peripheral nerves to thereby exertvarious physiological functions. This receptor was cloned in 1999 anddetermined for its gene sequence and amino acid sequence. However, itsamino acid sequence homology was as low as 22% and 21.4% with H1receptor and H2 receptor, respectively (see Non-patent Document 1). H3receptors are present in the presynaptic membrane and are shown to serveas autoreceptors controlling the synthesis and release of histamine (seeNon-patent Document 2). Moreover, H3 receptors are also shown to controlnot only the release of histamine, but also the release of otherneurotransmitters including acetylcholine, serotonin, dopamine andnoradrenaline (see Non-patent Document 3). It is also suggested that H3receptors would be active in the absence of agonists, and their activitycan be inhibited by compounds serving as inverse agonists. These factssuggest that H3 receptor antagonists or inverse agonists would enhancethe release of H3 receptor-regulated neurotransmitters and may serve astherapeutic agents for various diseases related to abnormal release ofthese neurotransmitters.

Experiments in animal models indicate a possibility that H3 receptorantagonists or inverse agonists can be used as therapeutic agents fordementia, Alzheimer's disease (see Non-patent Documents 4 and 5),attention-deficit hyperactivity disorder (see Non-patent Document 6),schizophrenia (see Non-patent Document 7), epilepsy, central convulsion,etc.

Moreover, it is shown that H3 receptors are involved in eating behavior(see Non-patent Document 8); and hence possible target diseases for H3receptor antagonists or inverse agonists also include metabolic diseasessuch as eating disorders, obesity, diabetes, hyperlipidemia, etc.

Further, it is shown that histamine regulates the circadian rhythm inthe brain and is responsible for maintaining a balance between wakingand sleeping states (see Non-patent Documents 9 and 10); and hencepossible target diseases for H3 receptor antagonists or inverse agonistsalso include sleep disorders and diseases associated with sleepdisorders such as narcolepsy, sleep apnea syndrome, circadian rhythmdisorder, depression, etc.

Furthermore, it is shown that H3 receptors are present in sympatheticnerves on the nasal mucosa, and there is a report showing that thecombined use of H3 and H1 receptor antagonists remarkably improves nasalcongestion (see Non-patent Document 11). This indicates a possibilitythat H3 receptor antagonists or inverse agonists are useful fortreatment of allergic rhinitis or other diseases, either alone or incombination with H1 receptor antagonists.

H3 receptor antagonists or inverse agonists have been summarized inseveral reviews (see Non-patent Documents 12 to 15), and reference maybe made to these reviews. In the early years, many reports were issuedfor imidazole compounds starting from histamine itself as a leadingcompound. However, these compounds have not yet been developed asmedicaments because they are feared to have negative effects such asinhibition of a drug-metabolizing enzyme, cytochrome P450 (CYP).

In recent years, many reports have been issued for non-imidazole H3receptor antagonists or inverse agonists (see Patent Documents 1 to 15).However, there is no report about compounds having the structuredisclosed in the present invention.

Patent Document 1: International Patent Publication No. WO2002/012190

Patent Document 2: International Patent Publication No. WO2002/040461

Patent Document 3: International Patent Publication No. WO2005/007644

Patent Document 4: International Patent Publication No. WO2005/097751

Patent Document 5: International Patent Publication No. WO2005/097778

Patent Document 6: International Patent Publication No. WO2005/118547

Patent Document 7: International Patent Publication No. WO2006/014136

Patent Document 8: International Patent Publication No. WO2006/023462

Patent Document 9: International Patent Publication No. WO2006/045416

Patent Document 10: International Patent Publication No. WO2006/046131

Patent Document 11: International Patent Publication No. WO2006/059778

Patent Document 12: International Patent Publication No. WO2006/061193

Patent Document 13: International Patent Publication No. WO2006/107661

Patent Document 14: International Patent Publication No. WO2006/103057

Patent Document 15: International Patent Publication No. WO2007/094962

Non-patent Document 1: Lovenberg T. W. et al., Molecular pharmacology,55, 1101-1107, 1999

Non-patent Document 2: Arrang J-M. et al., Nature, 302, 832-837, 1983

Non-patent Document 3: Brown R. E. et al., Progress in Neurobiology, 63,637-672, 2001

Non-patent Document 4: Huang Y-W. et al., Behavioural Brain Research,151, 287-293, 2004

Non-patent Document 5: Komater V. A. et al., Behavioural Brain Research,159, 295-300, 2005

Non-patent Document 6: Passani M. B. et al., Neuroscience andBiobehavioral Reviews, 24, 107-113, 2000

Non-patent Document 7: Fox G. B. et al., J. Pharmacol. Exp. Ther., 313,176-190,

Non-patent Document 8: Hancock A. A. et al., Curr. Opin. Investig. Drug,4, 1190-1197

Non-patent Document 9: Huang Z-L. et al., Prog. Natr. Acad. Sci., 103,4687-4692, 2006

Non-patent Document 10: Babier A. J. et al., Br. J. Pharmacol., 143,649-661, 2004

Non-patent Document 11: McLeod R. L. et al., Am. J. Rhinol., 13,391-399, 1999

Non-patent Document 12: Schwartz J. C. et al., Trends in Pharmacol.Sci., 7, 24-28, 1986

Non-patent Document 13: Passani M. B. et al., Trends in Pharmacol. Sci.,25, 618-625, 2004

Non-patent Document 14: Leurs R. et al., Nature Drug Discovery, 4,107-122, 2005

Non-patent Document 15: Leurs R. et al., Drug Discovery Today, 10,1613-1627, 2005

DISCLOSURE OF THE INVENTION Problems to be Solved by the Invention

The object of the present invention is to provide phenylpyrazolederivatives, more specifically phenylpyrazole derivatives which have astrong inhibitory effect against binding to histamine H3 receptors andwhich are useful for prevention or treatment of histamine H3receptor-mediated disorders such as dementia, Alzheimer's disease,attention-deficit hyperactivity disorder, schizophrenia, epilepsy,central convulsion, eating disorders, obesity, diabetes, hyperlipidemia,sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythmdisorder, depression, allergic rhinitis or other diseases.

Means for Solving the Problems

As a result of extensive and intensive efforts, the inventors of thepresent invention have found that phenylpyrazole derivatives having aspecific substituent at the 4-position of pyrazole have a stronginhibitory activity against histamine H3 receptors. This finding led tothe completion of the present invention.

Embodiments will be given below for the phenylpyrazole derivatives ofthe present invention (hereinafter referred to as “the compounds of thepresent invention”).

[1] A phenylpyrazole derivative represented by formula (1) or apharmaceutically acceptable salt thereof:

{wherein

R¹ and R², which may be the same or different, each represent C₁-C₆alkyl or C₃-C₈ cycloalkyl, or

R¹ and R² are attached to each other together with their adjacentnitrogen atom to form a 4- to 7-membered saturated heterocyclic ring(wherein said saturated heterocyclic ring may be substituted withhalogen or C₁-C₆ alkyl),

n represents an integer of 0 to 2,

T represents a hydrogen atom, halogen or C₁-C₆ alkyl, and

R represents any one of formulae (I) to (VIII):

(wherein Z¹ and Z², which may be the same or different, each represent—CH₂—, —O— or —NR¹¹—,

p represents an integer of 0 to 3,

q represents an integer of 0 to 1,

r and s, which may be the same or different, each represent an integerof 0 to 2,

R³ represents halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or oxo(provided that when Z¹ is —CH₂—, the hydrogen atom(s) may be replaced byR³),

R⁴ and R⁵, which may be the same or different, each represent a hydrogenatom, C₁-C₆ alkyl (wherein said C₁-C₆ alkyl may be substituted withhalogen, C₃-C₈ cycloalkyl, C₁-C₆ alkoxy, hydroxy, hydroxy-C₁-C₆ alkoxy,C₂-C₇ alkoxycarbonyl or carboxy), C₃-C₈ cycloalkyl (wherein said C₃-C₈cycloalkyl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy orhydroxy) or the formula —(CH₂)_(m)—Ar¹ (wherein Ar¹ represents aryl(wherein said aryl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆alkoxy, hydroxy or cyano) or heteroaryl (wherein said heteroaryl may besubstituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano),and m represents an integer of 0 to 2),

R⁶ represents halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or oxo(provided that when Z² is —CH₂—, the hydrogen atom(s) may be replaced byR⁶),

R⁷ represents a hydrogen atom or C₁-C₆ alkyl,

R⁸ represents C₁-C₆ alkyl (wherein said C₁-C₆ alkyl may be substitutedwith halogen, C₃-C₈ cycloalkyl, C₁-C₆ alkoxy or hydroxy), C₃-C₈cycloalkyl (wherein said C₃-C₈ cycloalkyl may be substituted withhalogen, C₁-C₆ alkyl, C₁-C₆ alkoxy or hydroxy), C₁-C₆ alkoxy (whereinsaid C₁-C₆ alkoxy may be substituted with halogen, C₃-C₈ cycloalkyl,C₁-C₆ alkoxy or hydroxy) or the formula —(CH₂)₁—Ar² (wherein Ar²represents aryl (wherein said aryl may be substituted with halogen,C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano) or heteroaryl (wherein saidheteroaryl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy,hydroxy or cyano), and 1 represents an integer of 0 to 2),

G represents —CO— or —SO₂—,

R⁹ represents C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₁-C₆ alkoxy, aryl (whereinsaid aryl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy,hydroxy or cyano) or heteroaryl (wherein said heteroaryl may besubstituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano),

R¹⁰ represents C₁-C₆ alkyl, C₁-C₆ alkoxy, amino, C₁-C₆ alkylamino,C₂-C₁₂ dialkylamino, a 4- to 7-membered saturated heterocyclic ring(wherein said saturated heterocyclic ring may be substituted withhalogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano), aryl (whereinsaid aryl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy,hydroxy or cyano) or heteroaryl (wherein said heteroaryl may besubstituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano),and

R¹¹ represents hydrogen or C₁-C₆ alkyl)}.

[2] A phenylpyrazole derivative represented by formula (1) or apharmaceutically acceptable salt thereof:

{wherein

R¹ and R², which may be the same or different, each represent C₁-C₆alkyl or C₃-C₈ cycloalkyl, or

R¹ and R² are attached to each other together with their adjacentnitrogen atom to form a 4- to 7-membered saturated heterocyclic ring(wherein said saturated heterocyclic ring may be substituted withhalogen or C₁-C₆ alkyl),

n represents an integer of 0 to 2,

T represents a hydrogen atom, halogen or C₁-C₆ alkyl, and

R represents any one of formulae (I) to (VIII):

(wherein Z¹ and Z², which may be the same or different, each represent—CH₂—, —O— or —NH—,

p represents an integer of 0 to 3,

q represents an integer of 0 to 1,

r and s, which may be the same or different, each represent an integerof 0 to 2,

R³ represents halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy or hydroxy (providedthat when Z¹ is —CH₂— or —NH—, the hydrogen atom(s) may be replaced byR³),

R⁴ and R⁵, which may be the same or different, each represent a hydrogenatom, C₁-C₆ alkyl (wherein said C₁-C₆ alkyl may be substituted withhalogen, C₃-C₈ cycloalkyl, C₁-C₆ alkoxy or hydroxy), C₃-C₈ cycloalkyl(wherein said C₃-C₈ cycloalkyl may be substituted with halogen, C₁-C₆alkyl, C₁-C₆ alkoxy or hydroxy) or the formula —(CH₂)_(m)—Ar¹ (whereinAr¹ represents aryl (wherein said aryl may be substituted with halogen,C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano) or heteroaryl (wherein saidheteroaryl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy,hydroxy or cyano), and m represents an integer of 0 to 2),

R⁶ represents halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or oxo(provided that when Z² is —CH₂— or —NH—, the hydrogen atom(s) may bereplaced by R⁶, and provided that when Z² is —NH—, R⁶ is halogen, C₁-C₆alkyl, C₁-C₆ alkoxy or hydroxy),

R⁷ represents a hydrogen atom or C₁-C₆ alkyl,

R⁸ represents C₁-C₆ alkyl (wherein said C₁-C₆ alkyl may be substitutedwith halogen, C₃-C₈ cycloalkyl, C₁-C₆ alkoxy or hydroxy), C₃-C₈cycloalkyl (wherein said C₃-C₈ cycloalkyl may be substituted withhalogen, C₁-C₆ alkyl, C₁-C₆ alkoxy or hydroxy), C₁-C₆ alkoxy (whereinsaid C₁-C₆ alkoxy may be substituted with halogen, C₃-C₈ cycloalkyl,C₁-C₆ alkoxy or hydroxy) or the formula —(CH₂)₁—Ar² (wherein Ar²represents aryl (wherein said aryl may be substituted with halogen,C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano) or heteroaryl (wherein saidheteroaryl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy,hydroxy or cyano), and 1 represents an integer of 0 to 2),

G represents —CO— or —SO₂—,

R⁹ represents C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₁-C₆ alkoxy, aryl (whereinsaid aryl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy,hydroxy or cyano) or heteroaryl (wherein said heteroaryl may besubstituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano),and

R¹⁰ represents C₁-C₆ alkyl, C₁-C₆ alkoxy, amino, C₁-C₆ alkylamino,C₂-C₁₂ dialkylamino, a 4- to 7-membered saturated heterocyclic ring(wherein said saturated heterocyclic ring may be substituted withhalogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano), aryl (whereinsaid aryl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy,hydroxy or cyano) or heteroaryl (wherein said heteroaryl may besubstituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy orcyano))}.

[3] A phenylpyrazole derivative represented by formula (1) or apharmaceutically acceptable salt thereof:

{wherein

R¹ and R², which may be the same or different, each represent C₁-C₆alkyl or C₃-C₈ cycloalkyl, or

R¹ and R² are attached to each other together with their adjacentnitrogen atom to form a 4- to 7-membered saturated heterocyclic ring(wherein said saturated heterocyclic ring may be substituted withhalogen or C₁-C₆ alkyl),

n represents an integer of 0 to 2,

T represents a hydrogen atom, halogen or C₁-C₆ alkyl, and

R represents any one of formulae (I) to (VIII):

(wherein Z¹ and Z², which may be the same or different, each represent acarbon atom or an oxygen atom,

p represents an integer of 0 to 2,

q represents an integer of 0 to 1,

r and s, which may be the same or different, each represent an integerof 0 to 2,

R³ represents halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy or hydroxy,

R⁴ and R⁵, which may be the same or different, each represent a hydrogenatom, C₁-C₆ alkyl (wherein said C₁-C₆ alkyl may be substituted withhalogen, C₃-C₈ cycloalkyl, C₁-C₆ alkoxy or hydroxy), C₃-C₈ cycloalkyl(wherein said C₃-C₈ cycloalkyl may be substituted with halogen, C₁-C₆alkyl, C₁-C₆ alkoxy (wherein said C₁-C₆ alkoxy may be substituted withhalogen, C₃-C₈ cycloalkyl, C₁-C₆ alkoxy or hydroxy) or hydroxy) or theformula —(CH₂)_(m)—Ar¹ (wherein Ar¹ represents aryl (wherein said arylmay be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy orcyano) or heteroaryl (wherein said heteroaryl may be substituted withhalogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano), and m representsan integer of 0 to 2),

R⁶ represents halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or oxo,

R⁷ represents a hydrogen atom or C₁-C₆ alkyl,

R⁸ represents C₁-C₆ alkyl (wherein said C₁-C₆ alkyl may be substitutedwith halogen, C₃-C₈ cycloalkyl, C₁-C₆ alkoxy or hydroxy), C₃-C₈cycloalkyl (wherein said C₃-C₈ cycloalkyl may be substituted withhalogen, C₁-C₆ alkyl, C₁-C₆ alkoxy or hydroxy), C₁-C₆ alkoxy (whereinsaid C₁-C₆ alkoxy may be substituted with halogen, C₃-C₈ cycloalkyl,C₁-C₆ alkoxy or hydroxy) or the formula —(CH₂)₁—Ar² (wherein Ar²represents aryl (wherein said aryl may be substituted with halogen,C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano) or heteroaryl (wherein saidheteroaryl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy,hydroxy or cyano), and 1 represents an integer of 0 to 2),

G represents —CO— or —SO₂—,

R⁹ represents C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₁-C₆ alkoxy, aryl (whereinsaid aryl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy,hydroxy or cyano) or heteroaryl (wherein said heteroaryl may besubstituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano),and

R¹⁰ represents C₁-C₆ alkyl, C₁-C₆ alkoxy, amino, C₁-C₆ alkylamino,C₂-C₁₂ dialkylamino, a 4- to 7-membered saturated heterocyclic ring(wherein said saturated heterocyclic ring may be substituted withhalogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano), aryl (whereinsaid aryl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy,hydroxy or cyano) or heteroaryl (wherein said heteroaryl may besubstituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy orcyano))}.

[4] The phenylpyrazole derivative or pharmaceutically acceptable saltthereof according to any one of [1] to [3] above, wherein in formula(1),

n is 1,

T represents a hydrogen atom or halogen, and

R¹ and R² are attached to each other together with their adjacentnitrogen atom to form a 5- to 6-membered saturated heterocyclic ring(wherein said saturated heterocyclic ring may be substituted with C₁-C₆alkyl).

[5] The phenylpyrazole derivative or pharmaceutically acceptable saltthereof according to any one of [1] to [4] above, wherein in formula(1), R is formula (I).

[6] The phenylpyrazole derivative or pharmaceutically acceptable saltthereof according to any one of [1] to [4] above, wherein in formula(1), R is formula (II).

[7] The phenylpyrazole derivative or pharmaceutically acceptable saltthereof according to any one of [1] to [4] above, wherein in formula(1), R is formula (III).

[8] The phenylpyrazole derivative or pharmaceutically acceptable saltthereof according to [1] above, which is represented by the followingformula:

{wherein Z¹ represents —CH₂— or —O—,

p represents an integer of 0 to 3,

r represents an integer of 0 to 2,

T represents a hydrogen atom or halogen,

R³ represents halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or oxo(provided that when Z¹ is —CH₂—, the hydrogen atom(s) may be replaced byR³), and

R^(A) represents C₁-C₆ alkyl}.

[9] The phenylpyrazole derivative or pharmaceutically acceptable saltthereof according to [1] above, which is represented by the followingformula:

{wherein Z¹ represents —O— or —NR¹¹— (wherein R¹¹ represents hydrogen orC₁-C₆ alkyl),

p represents an integer of 0 to 3,

r represents an integer of 0 to 2, and

R³ represents halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or oxo}.

[10] The phenylpyrazole derivative or pharmaceutically acceptable saltthereof according to any one of [1] to [5] above, which is selected fromthe group consisting of:

-   4-{[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}morpholine,-   4-{[1-(4-{3-[(2S)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}morpholine,-   4-({1-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-1H-pyrazol-4-yl}carbonyl)morpholine,-   4-({1-[4-(3-piperidin-1-ylpropoxy)phenyl]-1H-pyrazol-4-yl}carbonyl)morpholine,-   4-[(1-{4-[3-(2,2-dimethylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)carbonyl]morpholine,

azetidin-1-yl-(1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)methanone,

-   4-[(3,3-difluoropyrrolidin-1-yl)carbonyl]-1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole,-   [(2R,6S)-2,6-dimethylmorpholin-4-yl][1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]methanone,-   [1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl](1,4-oxazepan-4-yl)methanone,-   (4-methylpiperazin-1-yl)[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]methanone,-   [1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl](pyrrolidin-1-yl)methanone,-   (1-{4-[3-(3-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)(morpholin-4-yl)methanone,-   (1-{4-[3-(2-ethylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)(morpholin-4-yl)methanone,-   (1-{4-[3-(2,2-difluoropyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)(morpholin-4-yl)methanone,-   [1-(4-{2-[(2R)-2-methylpyrrolidin-1-yl]ethoxy}phenyl)-1H-pyrazol-4-yl](morpholin-4-yl)methanone,-   [1-(4-{4-[(2R)-2-methylpyrrolidin-1-yl]butoxy}phenyl)-1H-pyrazol-4-yl](morpholin-4-yl)methanone,-   [1-(3-fluoro-4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl](morpholin-4-yl)methanone,-   [1-(2-methyl-4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl](morpholin-4-yl)methanone,-   [1-(3-bromo-4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl](morpholin-4-yl)methanone,    and-   (2-hydroxymorpholin-4-yl)[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]methanone.

[11] The phenylpyrazole derivative or pharmaceutically acceptable saltthereof according to any one of [1] to [4] and [6] above, which isselected from the group consisting of:

-   1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxamide,-   1-(4-{3-[(2S)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxamide,-   N-tert-butyl-1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazole-4-carboxamide,-   N-tert-butyl-1-{4-[3-(2,5-dimethylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazole-4-carboxamide,-   N-tert-butyl-1-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-1H-pyrazole-4-carboxamide,-   N-tert-butyl-1-{4-[3-(diethylamino)propoxy]phenyl}-1H-pyrazole-4-carboxamide,-   N-(4-fluorophenyl)-1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazole-4-carboxamide,-   N-(4-fluorophenyl)-1-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-1H-pyrazole-4-carboxamide,-   N-(4-methylphenyl)-1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazole-4-carboxamide,-   1-{4-[3-(2-methylpyrrolidin-1-yl)-propoxy]-phenyl}-1H-pyrazole-4-carboxylic    acid 4-fluorobenzylamide,-   1-{4-[3-(2-methylpyrrolidin-1-yl)-propoxy]-phenyl}-1H-pyrazole-4-carboxylic    acid dimethylamide,-   1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxylic    acid bis-(2-hydroxyethyl)-amide,-   N-(2-hydroxyethyl)-1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxamide,-   tert-butyl    N-(2-hydroxyethyl)-N-{[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}glycinate,-   N-(2-hydroxyethyl)-N-{[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}glycine,    and-   N-[2-(2-hydroxyethoxy)ethyl]-1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxamide.

[12] A prophylactic or therapeutic agent for dementia, Alzheimer'sdisease, attention-deficit hyperactivity disorder, schizophrenia,epilepsy, central convulsion, eating disorders, obesity, diabetes,hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome,circadian rhythm disorder, depression or allergic rhinitis, whichcomprises the phenylpyrazole derivative or pharmaceutically acceptablesalt thereof according to any one of [1] to [11] above as an activeingredient.

ADVANTAGES OF THE INVENTION

The compounds of the present invention are excellent histamine H3receptor antagonists or inverse agonists.

BEST MODE FOR CARRYING OUT THE INVENTION

The terms and expressions used herein are defined as follows.

As used herein, the term “halogen” refers to a fluorine atom, a chlorineatom, a bromine atom or an iodine atom.

The term “C₁-C₆ alkyl” refers to a linear or branched alkyl groupcontaining 1 to 6 carbon atoms, including methyl, ethyl, n-propyl,isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl,isopentyl, neopentyl and n-hexyl groups.

The term “C₃-C₈ cycloalkyl” refers to a cyclic alkyl group containing 3to 8 carbon atoms, including cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, cycloheptyl and cyclooctyl groups.

The term “C₁-C₆ alkoxy” refers to a linear or branched alkoxy groupcontaining 1 to 6 carbon atoms, including methoxy, ethoxy, n-propoxy,isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentyloxy,isopentyloxy, neopentyloxy and n-hexyloxy groups.

The term “C₂-C₇ alkoxycarbonyl” refers to a carbonyl group attached to alinear or branched alkoxy group containing 1 to 6 carbon atoms,including methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl,isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl,sec-butoxycarbonyl, tert-butoxycarbonyl, n-pentyloxycarbonyl,isopentyloxycarbonyl, neopentyloxycarbonyl and n-hexyloxycarbonylgroups.

The term “hydroxy-C₁-C₆ alkoxy” refers to a hydroxy-substituted linearor branched alkoxy group containing 1 to 6 carbon atoms, including2-hydroxyethoxy, 2-hydroxy-n-propoxy, 3-hydroxy-n-propoxy,2-hydroxy-1-methylethoxy and 6-hydroxy-n-hexyloxy groups.

The term “C₁-C₆ alkylamino” refers to an amino group substituted with alinear or branched alkyl group containing 1 to 6 carbon atoms, includingmethylamino, ethylamino, n-propylamino, isopropylamino, n-butylamino,isobutylamino, sec-butylamino, tert-butylamino, n-pentylamino,isopentylamino, neopentylamino and n-hexylamino groups.

The term “C₂-C₁₂ dialkylamino” refers to an amino group substituted withtwo linear or branched alkyl groups each containing 1 to 6 carbon atoms,including dimethylamino, diethylamino, di-n-propylamino,N,N-isopropylmethylamino, di-n-butylamino, diisobutylamino,N,N-sec-butylethylamino, N,N-tert-butylmethylamino, di-n-pentylamino,N,N-isopentylmethylamino, N,N-neopentylmethylamino and di-n-hexylaminogroups.

The term “4- to 7-membered saturated heterocyclic ring” refers to, e.g.,a 1-azetidyl, 1-pyrrolidyl, piperidino, morpholino or 1-azepanyl group.

The expression “attached to each other together with their adjacentnitrogen atom to form a 4- to 7-membered saturated heterocyclic ring” isintended to mean, e.g., a 1-azetidyl, 1-pyrrolidyl, piperidino,morpholino or 1-azepanyl group.

The term “aryl” refers to a phenyl group or a naphthyl group.

The term “heteroaryl” refers to a group composed of a 5- or 6-memberedmonocyclic or 9- or 10-membered bicyclic aromatic heterocyclic ring.Examples include pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl,quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, pyrrolyl,furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl,thiazolyl, isothiazolyl, triazolyl, indolyl, benzofuranyl,benzothiophenyl, benzoimidazolyl, indazolyl, benzoxazolyl,benzothiazolyl and benzotriazolyl groups. More specific examples include2-pyridyl, 3-pyridyl, 4-pyridyl, pyridazin-3-yl, pyridazin-4-yl,pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl,quinolin-2-yl, quinolin-4-yl, quinolin-6-yl, quinolin-8-yl,isoquinolin-1-yl, isoquinolin-6-yl, quinazolin-2-yl, quinazolin-5-yl,quinoxalin-2-yl, quinoxalin-6-yl, pyrrol-3-yl, furan-2-yl, furan-3-yl,thiophen-2-yl, thiophen-3-yl, pyrazol-3-yl, pyrazol-4-yl, imidazol-2-yl,oxazol-2-yl, oxazol-4-yl, isoxazol-3-yl, thiazol-2-yl, thiazol-5-yl,isothiazol-4-yl, 1,2,4-triazol-3-yl, indol-2-yl, indol-5-yl, indol-7-yl,benzofuran-3-yl, benzothiophen-3-yl, benzoimidazol-2-yl, indazol-5-yl,benzoxazol-2-yl, benzothiazol-2-yl and benzotriazol-4-yl groups.

Preferred embodiments will be given below for the compounds of thepresent invention.

n is preferably 1.

T is preferably a hydrogen atom or halogen.

One preferred embodiment of R is formula (I) shown below.

In formula (I), Z¹ represents —CH₂—, —O— or —NR¹¹— (wherein R¹¹represents hydrogen or C₁-C₆ alkyl),

p represents an integer of 0 to 3,

r represents an integer of 0 to 2, and

R³ represents halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or oxo(provided that when Z¹ is —CH₂—, the hydrogen atom(s) may be replaced byR³).

Preferred embodiments for the structure of formula (I) are representedby the following formulae:

(wherein R³, R¹¹, p and r are as defined above).

R³ is preferably halogen, C₁-C₆ alkyl or hydroxy.

R¹¹ is preferably C₁-C₆ alkyl.

In formula (Ia), p preferably represents an integer of 1 to 2.

In formulae (Ib) and (Ic), p preferably represents an integer of 2 to 3.

A more preferred embodiment for the structure of formula (I) isrepresented by the following formula.

Another preferred embodiment of R is formula (II) shown below.

In formula (II), R⁴ and R⁵, which may be the same or different,preferably each represent a hydrogen atom, C₁-C₆ alkyl (wherein saidC₁-C₆ alkyl may be substituted with halogen, C₃-C₈ cycloalkyl, C₁-C₆alkoxy, hydroxy, or hydroxy-C₁-C₆ alkoxy) or the formula —(CH₂)_(m)—Ar¹(wherein Ar¹ represents aryl (wherein said aryl may be substituted withhalogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano), and m representsan integer of 0 to 2).

Yet another preferred embodiment of R is formula (III) shown below.

In formula (III), Z² represents —CH₂—, —O— or —NR¹¹— (wherein R¹¹represents hydrogen or C₁-C₆ alkyl),

q represents an integer of 0 to 1,

s represents an integer of 0 to 2, and

R⁶ represents halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or oxo(provided that when Z² is —CH₂—, the hydrogen atom(s) may be replaced byR⁶).

Preferred embodiments for the structure of formula (III) are representedby the following formulae:

(wherein R⁶, s and q are as defined above).

s preferably represents an integer of 0 to 1.

Likewise, in a preferred embodiment of —NR¹R², R¹ and R² are attached toeach other together with their adjacent nitrogen atom to form a 5- to6-membered saturated heterocyclic ring (e.g., 1-pyrrolidyl, piperidino)(wherein said saturated heterocyclic ring may be substituted with C₁-C₆alkyl). In the case of 1-pyrrolidyl, it is preferably substituted withone C₁-C₆ alkyl at the 2-position.

A more preferred embodiment of —NR¹R² is a group represented by thefollowing formula.

An even more preferred embodiment of —NR¹R² is a group represented bythe following formula.

Moreover, to determine pharmaceutical utility, various aspects ofcompounds should be evaluated, including not only their main activity,but also their side effects and toxicity. More specifically, whencompounds are targeted for H3 receptor inhibition, since opioidreceptors are involved in the regulatory mechanism of brain functions,the compounds may have side effects such as dependence, dysphoria,depression-like symptoms if they also have an affinity for μ, δ and κreceptors. On the other hand, when compounds have an antagonistic effectagainst σ1 receptors, they will affect acetylcholine release and NMDAreceptor functions, and hence cannot exert a sufficient enhancing effecton cognitive functions. These findings are reported in J. Pharmacol.Exp. Ther., 2002, Arp, 301(1), 249-257 and Neuropsychopharmacology,2007, March, 32(3), 514-521. Thus, there is a demand for compounds thathave no affinity for opioid receptors and selectively act on H3receptors.

Compounds preferred in terms of low affinity for opioid receptors arephenylpyrazole derivatives or pharmaceutically acceptable salts thereof,which have a specific substituent at the 4-position of pyrazole andfurther have other substituents as defined below:

{wherein Z¹ represents —O— or —NR¹¹— (wherein R¹¹ represents hydrogen orC₁-C₆ alkyl),

p represents an integer of 0 to 3,

r represents an integer of 0 to 2, and

R³ represents halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or oxo}.

A preferred embodiment for the above formula is as follows: Z¹ ispreferably —O—, R³ is preferably halogen, C₁-C₆ alkyl or hydroxy, and ris preferably 0.

Compounds preferred in terms of low cytotoxicity are phenylpyrazolederivatives or pharmaceutically acceptable salts thereof, which have aspecific substituent at the 4-position of pyrazole and further haveother substituents as defined below:

{wherein Z¹ represents —CH₂— or —O—,

p represents an integer of 0 to 3,

r represents an integer of 0 to 2,

T represents a hydrogen atom or halogen,

R³ represents halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or oxo(provided that when Z¹ is —CH₂—, the hydrogen atom(s) may be replaced byR³), and

R^(A) represents C₁-C₆ alkyl}.

A preferred embodiment for the above formula is as follows: Z¹ ispreferably —O—, R^(A) is preferably methyl, R³ is preferably C₁-C₆ alkylor hydroxy, and r is preferably 0.

As used herein, the term “pharmaceutically acceptable salt” is intendedto include a salt with an inorganic acid such as sulfuric acid,hydrochloric acid, hydrobromic acid, phosphoric acid or nitric acid; asalt with an organic acid such as acetic acid, oxalic acid, lactic acid,tartaric acid, fumaric acid, maleic acid, citric acid, benzenesulfonicacid, methanesulfonic acid, p-toluenesulfonic acid, benzoic acid,camphorsulfonic acid, ethanesulfonic acid, glucoheptonic acid, gluconicacid, glutamic acid, glycolic acid, malic acid, malonic acid, mandelicacid, galactaric acid or naphthalene-2-sulfonic acid; a salt with one ormore metal ions such as lithium ion, sodium ion, potassium ion, calciumion, magnesium ion, zinc ion and/or aluminum ion; as well as a salt withammonia or an amine such as arginine, lysine, piperazine, choline,diethylamine, 4-phenylcyclohexylamine, 2-aminoethanol or benzathine.

The compounds of the present invention may be present in the form ofvarious solvates. They may also be in hydrate form in terms ofapplicability as pharmaceutical preparations.

The compounds of the present invention encompass all of the following:enantiomers, diastereomers, equilibrium compounds, mixtures thereof atany ratio, racemates, etc.

The compounds of the present invention also encompass compounds in whichone or more hydrogen atoms, carbon atoms, nitrogen atoms, oxygen atomsor sulfur atoms are replaced by their radioisotopes or stable isotopes.These labeled compounds are useful for metabolism and/orpharmacokinetics study, biological analysis as receptor ligands, orother purposes.

The compounds of the present invention may be formulated intopharmaceutical preparations in combination with one or morepharmaceutically acceptable carriers, excipients or diluents. Examplesof such carriers, excipients and diluents include water, lactose,dextrose, fructose, sucrose, sorbitol, mannitol, polyethylene glycol,propylene glycol, starch, gum, gelatin, alginate, calcium silicate,calcium phosphate, cellulose, water syrup, methylcellulose,polyvinylpyrrolidone, alkyl parahydroxy benzosorbate, talc, magnesiumstearate, stearic acid, glycerine, as well as various oils such assesame oil, olive oil, soybean oil, and the like.

Moreover, the above carriers, excipients or diluents may optionally beblended with commonly used additives such as extenders, binders,disintegrating agents, pH adjustors, solubilizers and so on, and thenformulated using standard techniques into oral or parenteral dosageforms including tablets, pills, capsules, granules, powders, solutions,emulsions, suspensions, ointments, injections, skin plasters, etc. Thecompounds of the present invention may be given to adult patients at0.001 to 500 mg per administration, once or several times a day, by theoral or parenteral route. This dosage may be increased or decreased asappropriate for the type of disease to be treated, the age, body weightand symptom of a patient, etc.

Profiles desired for the compounds of the present invention includeexcellent efficacy, good in vivo kinetics (good oral absorption, notissue-specific accumulation), excellent physical properties, lowtoxicity, etc.

The compounds of the present invention can be prepared in the followingmanner. (Process for preparing the compounds of the present invention)

The compounds of the present invention can be prepared by known organicchemistry procedures, for example, according to the following reactionschemes. In Reaction Schemes 1 to 10 shown below, R, R¹ to R¹⁰, T, G,Z¹, Z², p, q, r, s and n are as defined above. X¹ to X³, which may bethe same or different, each represent a leaving group such as a halogenatom (e.g., a chlorine atom, a bromine atom, an iodine atom) or anorganic sulfonyloxy group (e.g., a methanesulfonyloxy group, abenzenesulfonyloxy group, a p-toluenesulfonyloxy group, atrifluoromethanesulfonyloxy group), Y¹ to Y⁴, which may be the same ordifferent, each represent a leaving group (e.g., a halogen atom or anorganic sulfonyloxy group) or a hydroxyl group, Z³ represents a carbonatom or an oxygen atom, and t represents an integer of 0 or 1.

Explanation will be given below of the process shown in Reaction Scheme1 for preparing the compound of the present invention. This process isintended to prepare the compound (1) of the present invention fromcompound (2).

(Step 1)

Step 1 is intended to obtain compound (4) by coupling reaction betweencompound (2) and known compound (3). Compound (2) is known or may beeasily synthesized from a known compound. This coupling reaction may beaccomplished by standard procedures for reaction between phenol andalkyl halide in the presence of a base with or without a solvent. Ifnecessary, for example, an additive such as potassium iodide or sodiumbromide may be added. Examples of a base available for use in thisreaction include pyridine, triethylamine, diisopropylethylamine,potassium tert-butoxide, potassium carbonate, cesium carbonate, sodiumbicarbonate, sodium hydroxide, potassium hydroxide, and sodium hydride.Examples of a solvent available for use in this reaction includealcohols (e.g., methanol, ethanol, isopropanol); ethers (e.g.,tetrahydrofuran, 1,4-dioxane); hydrocarbons (e.g., toluene, benzene);halogenated hydrocarbons (e.g., chloroform, dichloromethane); amides(e.g., N,N-dimethylformamide, N,N-dimethylacetamide,N-methyl-2-pyrrolidone); ketones (e.g., acetone, 2-butanone); dimethylsulfoxide; acetonitrile; water; or mixed solvents thereof. Among them,preferred are tetrahydrofuran, N,N-dimethylformamide, acetonitrile, and2-butanone. The reaction temperature in this reaction generally rangesfrom 0° C. to 150° C., preferably from 15° C. to 100° C., and thereaction time generally ranges from 1 to 48 hours, preferably from 1 to12 hours.

(Step 2)

Step 2 is intended to obtain compound (6) by condensation betweencompounds (4) and (5) through coupling reaction. Compound (5) is knownor may be easily synthesized from a known compound. This couplingreaction may be accomplished by standard procedures for reaction betweenamine and alkyl halide in the presence or absence of a base with orwithout a solvent. If necessary, for example, an additive such aspotassium iodide or sodium bromide may be added. Examples of a baseavailable for use in this reaction include pyridine, triethylamine,diisopropylethylamine, potassium tert-butoxide, potassium carbonate,cesium carbonate, sodium bicarbonate, sodium hydroxide, potassiumhydroxide, and sodium hydride. Examples of a solvent available for usein this reaction include alcohols (e.g., methanol, ethanol,isopropanol); ethers (e.g., tetrahydrofuran, 1,4-dioxane); hydrocarbons(e.g., toluene, benzene); halogenated hydrocarbons (e.g., chloroform,dichloromethane); amides (e.g., N,N-dimethylformamide,N,N-dimethylacetamide, N-methyl-2-pyrrolidone); ketones (e.g., acetone,2-butanone); dimethyl sulfoxide; acetonitrile; water; or mixed solventsthereof. Among them, preferred are tetrahydrofuran,N,N-dimethylformamide, and acetonitrile. The reaction temperature inthis reaction generally ranges from 0° C. to 150° C., preferably from15° C. to 100° C., and the reaction time generally ranges from 1 to 48hours, preferably from 1 to 12 hours.

(Step 3a)

Step 3a is intended to obtain the compound (1) of the present inventionby condensation between compounds (6) and (7) through coupling reaction.Compound (7) is known or may be easily synthesized from a knowncompound. This coupling reaction may be accomplished by standardprocedures for aromatization of a nitrogen atom in an azole compound inthe presence of a base using a ligand and a catalyst in a solvent, forexample, according to the method described in Kunz et al., Synlett,2003, vol. 15, pp. 2428-2439 or equivalent methods thereof. Examples ofa catalyst available for use in this reaction include copper catalystscommonly used for condensation reaction, as exemplified by copper(0),copper(I) iodide, copper(I) chloride, copper(I) oxide, copper(I) bromidetristriphenylphosphine complex, and copper(I) trifluoromethanesulfonantebenzene complex. Examples of a ligand available for use in this reactioninclude those commonly used for condensation reaction in the presence ofa copper catalyst, as exemplified by N,N′-dimethylethylenediamine,N,N′-dimethylcyclohexane-1,2-diamine, 2-aminopyridine,1,10-phenanthroline, 2-hydroxybenzaldehyde oxime, and ethylene glycol.Examples of a base available for use in this reaction include potassiumcarbonate, potassium phosphate, potassium hydroxide, potassiumtert-butoxide, cesium carbonate, sodium carbonate, sodium bicarbonate,sodium acetate, sodium methoxide, and tetrabutylammonium hydroxide.Among them, preferred are potassium carbonate and cesium carbonate.Examples of a solvent available for use in this reaction includealcohols (e.g., methanol, ethanol, isopropanol); ethers (e.g.,tetrahydrofuran, 1,4-dioxane); hydrocarbons (e.g., toluene, benzene);halogenated hydrocarbons (e.g., chloroform, dichloromethane); amides(e.g., N,N-dimethylformamide, N,N-dimethylacetamide,N-methyl-2-pyrrolidone); ketones (e.g., acetone, 2-butanone); dimethylsulfoxide; acetonitrile; water; or mixed solvents thereof. Among them,preferred are toluene, N,N-dimethylformamide, andN-methyl-2-pyrrolidone. The reaction temperature in this reactiongenerally ranges from 0° C. to 150° C., preferably from 40° C. to 120°C., and the reaction time generally ranges from 1 to 48 hours,preferably from 1 to 12 hours.

(Step 4)

Alternatively, compound (6) can also be obtained by coupling reactionbetween compounds (2) and (8). Compound (8) is known or may be easilysynthesized from a known compound. This coupling reaction may beaccomplished in the same manner as shown in Step 1 when Y¹ is a leavinggroup such as a halogen atom.

When Y¹ is a hydroxyl group, this coupling reaction may be Mitsunobureaction, for example, which is accomplished in a solvent in thepresence of a reagent composed of an organophosphorus compound (e.g.,triphenylphosphine, tributylphosphine) in combination with an azocompound (e.g., diethyl azodicarboxylate, diisopropyl azodicarboxylate,di-tert-butyl azodicarboxylate) or in the presence of a phosphorus ylidereagent (e.g., cyanomethyltributylphosphorane). Examples of a solventavailable for use in this reaction include ethers (e.g.,tetrahydrofuran, 1,4-dioxane); hydrocarbons (e.g., toluene, benzene);halogenated hydrocarbons (e.g., chloroform, dichloromethane); amides(e.g., N,N-dimethylformamide, N,N-dimethylacetamide,N-methyl-2-pyrrolidone); dimethyl sulfoxide; acetonitrile; or mixedsolvents thereof. Among them, preferred are tetrahydrofuran and toluene.The reaction temperature in this reaction generally ranges from 0° C. to120° C., preferably from 15° C. to 80° C., and the reaction timegenerally ranges from 1 to 48 hours, preferably from 1 to 12 hours.

Explanation will be given below of the process shown in Reaction Scheme3 for preparing the compound of the present invention. This process isintended to prepare the compound (1-2) or (1-3) of the present inventionfrom compound (1-1).

(Step 5)

Step 5 is intended to obtain compound (9) by hydrolysis of theethoxycarbonyl group in compound (1-1) into a carboxylic acid form. Thishydrolysis reaction may be accomplished by standard reaction for esterhydrolysis, for example, in the presence of a strong acid with orwithout a solvent, or alternatively, in the presence of a base in asolvent, according to the method described in T. W. Greene and P. G. M.Wuts ed., Protective Groups in Organic Synthesis, third edition, JohnWiley and Sons or equivalent methods thereof. The reaction temperaturein this reaction generally ranges from 0° C. to 120° C., preferably from15° C. to 80° C., and the reaction time generally ranges from 1 to 48hours, preferably from 1 to 12 hours.

(Step 6a)

Step 6a is intended to obtain the compound (1-2) or (1-3) of the presentinvention by condensation between compound (9) and compound (10) or(11), respectively, through coupling reaction. Compounds (10) and (11)are known or may be easily synthesized from known compounds. Thiscoupling reaction may be accomplished by standard procedures foramidation of a carboxylic acid, for example, through conversion of acarboxylic acid into a carboxylic acid halide (e.g., carboxylic acidchloride, carboxylic acid bromide) and the subsequent reaction with anamine, through reaction of a mixed acid anhydride (e.g., obtained from acarboxylic acid and a chlorocarbonate ester) with an amine, throughconversion of a carboxylic acid into an active ester (e.g.,1-benzotriazolyl ester, succinimidyl ester) and the subsequent reactionwith an amine, or through reaction of a carboxylic acid with an amine inthe presence of a dehydration condensing agent. All of these reactionsmay be accomplished in the presence or absence of a base in a solvent.Examples of a dehydration condensing agent available for use in thisreaction include 3-(3-dimethylaminopropyl)-1-ethylcarbodiimidehydrochloride, dicyclohexylcarbodiimide, diphenylphosphorylazide, andcarbonyldiimidazole. If necessary, it is possible to use an activatorsuch as 1-hydroxybenzotriazole or hydroxysuccinimide. Examples of a baseavailable for use in this reaction include pyridine, triethylamine,diisopropylethylamine, potassium carbonate, sodium carbonate, and sodiumbicarbonate. Examples of a solvent available for use in this reactioninclude ethers (e.g., tetrahydrofuran, 1,4-dioxane); hydrocarbons (e.g.,toluene, benzene); halogenated hydrocarbons (e.g., chloroform,dichloromethane); amides (e.g., N,N-dimethylformamide,N,N-dimethylacetamide, N-methyl-2-pyrrolidone); ketones (e.g., acetone,2-butanone); dimethyl sulfoxide; acetonitrile; water; or mixed solventsthereof. Among them, preferred is toluene, tetrahydrofuran orN,N-dimethylformamide. The reaction temperature in this reactiongenerally ranges from 0° C. to 120° C., preferably from 15° C. to 40°C., and the reaction time generally ranges from 1 to 48 hours,preferably from 1 to 12 hours.

(Step 7a)

Alternatively, the compound (1-2) or (1-3) of the present invention canalso be obtained by coupling reaction between compound (1-1) andcompound (10) or (11), respectively. This coupling reaction may beaccomplished by standard ester-amide exchange reaction for a carboxylicacid ester, for example, through reaction of a carboxylic acid esterwith a primary or secondary amine with or without a solvent. Ifnecessary, for example, an additive such as sodium methoxide, sodiumhydride, n-butyllithium or trimethylaluminum may be added. In the caseof using a solvent in this reaction, examples of a solvent includealcohols (e.g., methanol, ethanol, isopropanol); ethers (e.g.,tetrahydrofuran, 1,4-dioxane); hydrocarbons (e.g., toluene, benzene,xylene); amides (e.g., N,N-dimethylformamide, N,N-dimethylacetamide,N-methyl-2-pyrrolidone); ketones (e.g., acetone, 2-butanone); dimethylsulfoxide; acetonitrile; water; or mixed solvents thereof. Among them,preferred are toluene, tetrahydrofuran, and dimethyl sulfoxide. Thereaction temperature in this reaction generally ranges from 15° C. to150° C., preferably from 15° C. to 100° C., and the reaction timegenerally ranges from 1 to 48 hours, preferably from 1 to 12 hours.

Explanation will be given below of the process shown in Reaction Scheme5 for preparing the compound of the present invention. This process isintended to prepare the compound (1-4) or (1-5) of the present inventionfrom compound (9).

(Step 6b)

Step 6b is intended to obtain the compound (1-4) of the presentinvention by reaction between compound (9) and ammonia. This reactionmay be accomplished in the same manner as shown in Step 6a. Morespecifically, for example, it may be accomplished by reaction of acarboxylic acid with aqueous ammonia in the presence of a dehydrationcondensing agent.

(Step 8)

Step 8 is intended to obtain the compound (1-5) of the present inventionby conversion of the carbamoyl group in compound (1-4) into a nitrilegroup. This step may be accomplished by standard reaction for convertinga carbamoyl group into a nitrile group, for example, in the presence ofa dehydrating agent with or without a solvent. If necessary, forexample, an additive such as N,N-dimethylformamide or sodium chloridemay be added. Examples of a dehydrating agent available for use in thisreaction include phosphorus pentaoxide, phosphorus pentachloride,phosphorus trichloride, phosphoryl chloride, thionyl chloride, oxalylchloride, trifluoroacetic anhydride, and trifluoromethanesulfonicanhydride. In the case of using a solvent in this reaction, examples ofa solvent include ethers (e.g., tetrahydrofuran, 1,4-dioxane);hydrocarbons (e.g., toluene, benzene); amides (e.g.,N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidone);acetonitrile; or mixed solvents thereof. The reaction temperature inthis reaction generally ranges from 0° C. to 120° C., preferably from15° C. to 80° C., and the reaction time generally ranges from 1 to 48hours, preferably from 1 to 12 hours.

Explanation will be given below of the process shown in Reaction Scheme6 for preparing the compound of the present invention. This process isintended to prepare the compound (1-6), (1-7) or (1-8) of the presentinvention from compound (6).

(Step 3b)

Step 3b is intended to obtain the compound (1-6) of the presentinvention by condensation between compounds (6) and (7-1) throughcoupling reaction. This reaction may be accomplished in the same manneras shown in Step 3a.

(Step 9)

Step 9 is intended to obtain compound (12) by reduction of the nitrogroup in compound (1-6). This step may be accomplished by standardreduction reaction for converting a nitro group into an amino group, forexample, through catalytic reduction by hydrogenation in the presence ofa catalyst (e.g., palladium on carbon, platinum, Raney Nickel,rhodium-alumina), through reduction under acidic conditions using zinc,iron, tin or tin(II) chloride, or through reduction using a metalhydride (e.g., lithium aluminum hydride). More specifically, forexample, this step may be performed with the use of palladium on carbonas a catalyst in catalytic reduction by hydrogenation in a methanolsolvent.

(Step 10a)

Step 10a is intended to obtain the compound (1-7) of the presentinvention by condensation between compounds (12) and (13) throughcoupling reaction. Compound (13) is known or may be easily synthesizedfrom a known compound. This coupling reaction may be accomplished in thesame manner as shown in Step 6a when G is CO and Y² is a hydroxyl group.

When Y² is a halogen atom, this coupling reaction may be accomplished byreacting compound (12) with compound (13) in the presence or absence ofa base with or without a solvent. Examples of a base available for usein this reaction include pyridine, triethylamine, diisopropylethylamine,potassium carbonate, sodium bicarbonate, and sodium hydroxide. Examplesof a solvent available for use in this reaction include ethers (e.g.,tetrahydrofuran, 1,4-dioxane); hydrocarbons (e.g., toluene, benzene);halogenated hydrocarbons (e.g., chloroform, dichloromethane); amides(e.g., N,N-dimethylformamide, N,N-dimethylacetamide,N-methyl-2-pyrrolidone); or mixed solvents thereof. Among them,preferred are tetrahydrofuran and toluene. The reaction temperature inthis reaction generally ranges from 0° C. to 120° C., preferably from15° C. to 80° C., and the reaction time generally ranges from 1 to 48hours, preferably from 1 to 12 hours.

(Step 11)

Step 11 is intended to obtain the compound (1-8) of the presentinvention by reaction between compounds (1-7) and (14). Compound (14) isknown or may be easily synthesized from a known compound. This reactionmay be accomplished by standard procedures for alkylation of an amide orsulfonamide, for example, by reacting compound (1-7) with compound (14)in the presence of a base in a solvent. If necessary, for example, anadditive such as tetrabutylammonium bromide or 18-crown-6-ether may beadded. Examples of a base available for use in this reaction includesodium hydride, potassium hydride, potassium tert-butoxide, potassiumhydroxide, sodium hydroxide, sodium methoxide, and n-butyllithium.Examples of a solvent available for use in this reaction includealcohols (e.g., methanol, ethanol, isopropanol); ethers (e.g.,tetrahydrofuran, 1,4-dioxane); hydrocarbons (e.g., toluene, benzene);amides (e.g., N,N-dimethylformamide, N,N-dimethylacetamide,N-methyl-2-pyrrolidone); dimethyl sulfoxide; acetonitrile; water; ormixed solvents thereof. Among them, preferred are tetrahydrofuran andN,N-dimethylformamide. The reaction temperature in this reactiongenerally ranges from 0° C. to 150° C., preferably from 15° C. to 100°C., and the reaction time generally ranges from 1 to 48 hours,preferably from 1 to 12 hours.

Explanation will be given below of the process shown in Reaction Scheme7 for preparing the compound of the present invention. This process isintended to prepare the compound (1-8) of the present invention fromcompound (12).

(Step 12)

Step 12 is intended to obtain compound (15) by alkylation of the primaryamino group in compound (12). This alkylation reaction may beaccomplished by standard alkylation for converting a primary amino groupinto a secondary amino group, for example, through reaction in thepresence of a base using an alkylating agent (e.g., alkyl halide, alkylmethanesulfonate), through reductive amination with an aldehyde, throughconversion into an acid amide with a carboxylic acid or a derivativethereof and the subsequent reduction with a metal hydride (e.g.,borane), or through dehydration condensation with an alcohol.

(Step 10b)

Step 10b is intended to obtain the compound (1-8) of the presentinvention by condensation between compounds (15) and (13) throughcoupling reaction. This coupling reaction may be accomplished in thesame manner as shown in Step 10a.

Explanation will be given below of the process shown in Reaction Scheme8 for preparing the compound of the present invention. This process isintended to prepare the compound (1-9) or (1-10) of the presentinvention from compound (12).

(Step 10c)

Step 10c is intended to obtain the compound (1-9) of the presentinvention by condensation between compounds (12) and (16) throughcoupling reaction. Compound (16) is known or may be easily synthesizedfrom a known compound. This coupling reaction may be accomplished in thesame manner as shown in Step 10a.

(Step 13a)

Step 13a is intended to obtain the compound (1-10) of the presentinvention by intramolecular cyclization of compound (1-9). Thisintramolecular cyclization reaction may be accomplished according to themethod as described in, e.g., Journal of Medicinal Chemistry, 2002, vol.45, pp. 3972-3983 or equivalent methods thereof. Examples of a baseavailable for use in this reaction include sodium hydride, potassiumhydride, potassium carbonate, potassium tert-butoxide, and sodiumhydroxide. Examples of a solvent available for use in this reactioninclude ethers (e.g., tetrahydrofuran, 1,4-dioxane); hydrocarbons (e.g.,toluene, benzene); amides (e.g., N,N-dimethylformamide,N,N-dimethylacetamide, N-methyl-2-pyrrolidone); ketones (e.g., acetone,2-butanone); dimethyl sulfoxide; acetonitrile; or mixed solventsthereof. Among them, preferred are tetrahydrofuran and toluene. Thereaction temperature in this reaction generally ranges from 0° C. to150° C., preferably from 15° C. to 80° C., and the reaction timegenerally ranges from 1 to 48 hours, preferably from 1 to 12 hours.

Explanation will be given below of the process shown in Reaction Scheme9 for preparing the compound of the present invention. This process isintended to prepare the compound (1-11) of the present invention fromcompound (12).

(Step 14)

Step 14 is intended to obtain the compound (1-11) of the presentinvention by condensation between compounds (12) and (17). Compound (17)is known or may be easily synthesized from a known compound. Thiscondensation reaction may be accomplished by standard procedures forcondensation between amine and acid anhydride, for example, by reactingcompound (12) with compound (17) under heating conditions in thepresence or absence of an acid with or without a solvent. Examples of anacid available for use in this reaction include sulfuric acid, andhydrochloric acid. Examples of a solvent available for use in thisreaction include ethers (e.g., tetrahydrofuran, 1,4-dioxane);hydrocarbons (e.g., toluene, benzene); halogenated hydrocarbons (e.g.,chloroform, dichloromethane); or mixed solvents thereof. Among them,preferred is toluene or tetrahydrofuran. The reaction temperature inthis reaction generally ranges from 0° C. to 150° C., preferably from40° C. to 120° C., and the reaction time generally ranges from 1 to 48hours, preferably from 1 to 12 hours. Moreover, compound (18), which isa reaction intermediate in this step, may further be converted intocompound (1-11) by intramolecular dehydration cyclization. Thisdehydration cyclization reaction may be accomplished by standardprocedures for dehydration condensation, for example, by heating in thepresence of acetic anhydride with or without a solvent.

Explanation will be given below of the process shown in Reaction Scheme10 for preparing the compound of the present invention. This process isintended to prepare the compound (1-12) of the present invention fromcompound (12).

(Step 10d)

Step 10d is intended to obtain compound (20) by condensation betweencompounds (12) and (19) through coupling reaction. Compound (19) isknown or may be easily synthesized from a known compound. This couplingreaction may be accomplished in the same manner as shown in Step 10a.

(Step 15)

Step 15 is intended to convert compound (20) into compound (21). Thisconversion may be accomplished, for example, by reaction with lithiumaluminum hydride in a solvent.

(Step 16)

Step 16 is intended to obtain the compound (1-12) of the presentinvention by condensation between compounds (21) and (22) throughintermolecular cyclization. This intermolecular cyclization reaction maybe accomplished according to the method as described in, e.g., Journalof American Chemical Society, 1955, vol. 77, p. 633 or equivalentmethods thereof. Moreover, compound (23), which is a reactionintermediate in this step, may further be converted into compound (1-12)by intramolecular cyclization. This cyclization reaction may beaccomplished by standard procedures for alkylation of a hydroxyl groupwith an alkyl halide, for example, by heating in the presence of sodiumhydride with or without a solvent.

Explanation will be given below of the process shown in Reaction Scheme11 for preparing the compound of the present invention. This process isintended to prepare the compound (1-14) or (1-15) of the presentinvention from compound (1-13), i.e., the compound (1-2) of the presentinvention in which R⁴ is a 2-hydroxyethyl group and R⁵ is atert-butoxycarbonylmethyl group.

(Step 17)

Step 17 is intended to obtain the compound (1-14) of the presentinvention by hydrolysis of the tert-butoxycarbonyl group in compound(1-13) into a carboxylic acid form. This hydrolysis reaction may beaccomplished by standard reaction for ester hydrolysis, for example, inthe presence of a strong acid with or without a solvent, oralternatively, in the presence of a base in a solvent, according to themethod described in T. W. Greene and P. G. M. Wuts ed., ProtectiveGroups in Organic Synthesis, third edition, John Wiley and Sons orequivalent methods thereof. More specifically, for example, thehydrolysis reaction may be performed with trifluoroacetic acid in asolvent (e.g., chloroform) or with aqueous sodium hydroxide in a solvent(e.g., methanol). The reaction temperature in this reaction generallyranges from 0° C. to 120° C., preferably from 15° C. to 80° C., and thereaction time generally ranges from 1 to 48 hours, preferably from 1 to12 hours.

(Step 18)

Step 18 is intended to obtain the compound (1-15) of the presentinvention by intramolecular cyclization of compound (1-14). Thisintramolecular cyclization reaction may be accomplished by standardprocedures for converting a carboxylic acid into an ester, for example,through dehydration condensation between carboxylic acid and alcoholunder acidic conditions or in the presence of a dehydrating agent withor without a solvent.

The present invention will be further described in more detail by way ofthe following examples and test examples, which are not intended tolimit the scope of the invention.

The instrument data shown in the examples were obtained with themeasuring instruments listed below.

MS spectrum: SHIMADZU LCMS-2010EV or micromass Platform LC

NMR spectrum: JNM-ECA600 (JEOL Ltd., Japan)

IR spectrum: Spectrum One (Perkin Elmer)

Melting point: Thermoplus TG8120 (Rigaku Corporation, Japan)

Thermogravimetry: Thermoplus TG8120 (Rigaku Corporation, Japan)

Example 1 Preparation of1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxylicacid ethyl ester (1) Preparation of 1-(3-chloropropoxy)-4-iodobenzene

To a solution of 4-iodophenol (20.0 g) and 1-bromo-3-chloropropane (18.6g) in 2-butanone (200 mL), potassium carbonate (25.1 g) was added andstirred at 100° C. for 5 hours. The reaction mixture was cooled to roomtemperature, diluted with water and extracted with ethyl acetate. Theorganic layer was washed with water and brine, dried over sodium sulfateand concentrated under reduced pressure to give the titled compound(28.4 g) as an orange-colored oil.

(2) Preparation of (2R)-1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidine

A suspension of 1-(3-chloropropoxy)-4-iodobenzene obtained in Example1-(1) (2.79 g), (R)-2-methylpyrrolidine (0.961 g), sodium iodide (0.282g) and potassium carbonate (2.60 g) in acetonitrile (2.8 mL) was stirredin a sealed tube at 100° C. for 5 hours. The reaction mixture was cooledto room temperature, diluted with water and extracted with ethylacetate. The organic layer was washed with water and brine, dried oversodium sulfate and concentrated under reduced pressure. The resultingresidue was purified by silica gel column chromatography (elutingsolvent: n-hexane:ethyl acetate=10:1) to give the titled compound (3.27g) as a yellow oil.

(3) Preparation of1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxylicacid ethyl ester

A suspension of (2R)-1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidineobtained in Example 1-(2) (1.60 g), 1H-pyrazole-4-carboxylic acid ethylester (0.779 g), (rac-trans-N,N′-dimethylcyclohexane-1,2-diamine (0.263g), copper iodide (0.088 g) and cesium carbonate (3.02 g) inN,N-dimethylformamide (2.5 mL) was stirred at 120° C. for 4 hours. Thereaction mixture was cooled to room temperature, diluted with water andextracted with ethyl acetate. The organic layer was concentrated underreduced pressure, and the resulting residue was purified by silica gelcolumn chromatography (eluting solvent: n-hexane:ethyl acetate=3:1) togive the titled compound (1.11 g) as a yellow oil.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.09 (d, J=6.0 Hz, 3H), 1.37 (t,J=7.3 Hz, 3H), 1.39-1.45 (m, 1H), 1.65-1.73 (m, 1H), 1.74-1.82 (m, 1H),1.89-2.06 (m, 3H), 2.12 (q, J=8.7 Hz, 1H), 2.18-2.23 (m, 1H), 2.26-2.34(m, 1H), 2.95-3.02 (m, 1H), 3.18 (td, J=8.6, 2.5 Hz, 1H), 4.03-4.10 (m,2H), 4.33 (q, J=7.3 Hz, 2H), 6.99 (d, J=9.2 Hz, 2H), 7.58 (d, J=9.2 Hz,2H), 8.07 (s, 1H), 8.30 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 358 (M+H)⁺

Example 2 Preparation of1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxamide(1) Preparation of1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxylicacid hydrochloride

To1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxylicacid ethyl ester obtained in Example 1-(3) (1.11 g), concentratedhydrochloric acid (7.0 mL) was added at room temperature and stirred at80° C. for 2 hours. The reaction mixture was concentrated under reducedpressure to give the titled compound (1.08 g) as a light-brown solid.

(2) Preparation of1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxamide

To a suspension of1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxylicacid hydrochloride obtained in Example 2-(1) (1.08 g) inN,N-dimethylformamide (11 mL), 1-hydroxybenzotriazole monohydrate (0.539g) was added at room temperature and stirred for 5 minutes. To thereaction mixture, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimidehydrochloride (0.679 g) was added and stirred at room temperature for 30minutes, followed by addition of aqueous ammonia (25%, 0.702 g) andstirring overnight at room temperature. After addition of water andsaturated aqueous sodium bicarbonate, the reaction mixture was extractedwith ethyl acetate. The organic layer was washed with water and brine,dried over sodium sulfate and concentrated under reduced pressure. Theresulting residue was purified by silica gel column chromatography(eluting solvent: chloroform:methanol=20:1) to give the titled compound(0.504 g) as a colorless solid.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.08 (d, J=6.0 Hz, 3H), 1.36-1.46(m, 1H), 1.65-1.83 (m, 2H), 1.87-2.06 (m, 3H), 2.11 (q, J=9.0 Hz, 1H),2.17-2.24 (m, 1H), 2.25-2.33 (m, 1H), 2.93-3.03 (m, 1H), 3.13-3.20 (m,1H), 4.02-4.10 (m, 2H), 5.60 (br. s, 2H), 6.94-7.02 (m, 2H), 7.52-7.60(m, 2H), 7.91 (s, 1H), 8.29 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 329 (M+H)⁺

Example 3 Preparation of1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carbonitrile

To a solution of1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxamideobtained in Example 2-(2) (0.466 g) in N,N-dimethylformamide (5.0 mL),thionyl chloride (1.0 mL) was added dropwise under ice cooling andstirred at 0° C. for 30 minutes. The reaction mixture was adjusted to pH8 by addition of water and saturated aqueous sodium bicarbonate, andthen extracted with ethyl acetate. The organic layer was washed withbrine, dried over sodium sulfate and concentrated under reducedpressure. The resulting residue was purified by silica gel columnchromatography (eluting solvent: n-hexane:ethyl acetate=1:1), and theresulting crystal was washed with hexane:diisopropyl ether (1:1) to givethe titled compound (0.253 g) as a colorless solid.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.08 (d, J=6.0 Hz, 3H), 1.37-1.46(m, 1H), 1.65-1.83 (m, 2H), 1.88-2.06 (m, 3H), 2.11 (q, J=8.7 Hz, 1H),2.16-2.24 (m, 1H), 2.25-2.34 (m, 1H), 2.93-3.03 (m, 1H), 3.12-3.23 (m,1H), 4.02-4.11 (m, 2H), 6.95-7.02 (m, 2H), 7.50-7.57 (m, 2H), 7.95 (s,1H), 8.18 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 311 (M+H)⁺

Example 4 Preparation of1-(4-{3-[(2S)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxamide(1) Preparation of (2S)-1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidine

The same procedure as shown in Example 1-(2) was repeated to give thetitled compound, except that (R)-2-methylpyrrolidine was replaced by(S)-2-methylpyrrolidine.

(2) Preparation of1-(4-{3-[(2S)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxylicacid hydrochloride

The same procedures as shown in Example 1-(3) and Example 2-(1) wererepeated to give the titled compound, except that(2R)-1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidine was replaced by(2S)-1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidine obtained in Example4-(1).

(3) Preparation of1-(4-{3-[(2S)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxamide

The same procedure as shown in Example 2-(2) was repeated to give thetitled compound, except that1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxylicacid hydrochloride was replaced by1-(4-{3-[(2S)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxylicacid hydrochloride obtained in Example 4-(2).

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.08 (d, J=6.0 Hz, 3H) 1.37-1.44(m, 1H) 1.57-1.72 (m, 2H) 1.87-1.94 (m, 1H) 1.95-2.03 (m, 1H) 2.08-2.13(m, 2H) 2.16-2.22 (m, 1H) 2.25-2.32 (m, 1H) 2.94-3.00 (m, 1H) 3.19-3.24(m, 1H) 4.02-4.08 (m, 2H) 6.97 (d, J=8.7 Hz, 2H) 7.56 (d, J=8.7 Hz, 2H)7.93 (s, 1H) 8.30 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 329 (M+H)⁺

Example 5 Preparation of1-(4-{3-[(2S)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carbonitrile

The same procedure as shown in Example 3 was repeated to give the titledcompound, except that1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxamidewas replaced by1-(4-{3-[(2S)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxamideobtained in Example 4-(3).

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.08 (d, J=6.4 Hz, 3H) 1.38-1.44(m, 1H) 1.59-1.82 (m, 2H) 1.88-1.95 (m, 1H) 1.96-2.04 (m, 2H) 2.08-2.13(m, 1H) 2.16-2.23 (m, 1H) 2.25-2.34 (m, 1H) 2.93-3.01 (m, 1H) 3.14-3.20(m, 1H) 4.04-4.09 (m, 2H) 6.99 (d, J=9.2 Hz, 2H) 7.54 (d, J=9.2 Hz, 2H)7.95 (s, 1H) 8.18 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 311 (M+H)⁺

Example 6 Preparation of4-{[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}morpholine(1) Preparation of 4-(1H-pyrazol-4-ylcarbonyl)morpholine

A suspension of 1H-pyrazole-4-carboxylic acid (1.05 g),1-{3-(dimethylamino)propyl}-3-ethylcarbodiimide hydrochloride (2.5 g),1-hydroxybenzotriazole hydrate (1.6 g) and morpholine (1.2 g) inchloroform (18 mL) was stirred overnight at room temperature. Thereaction mixture was concentrated under reduced pressure, and theresulting residue was purified by NH-type silica gel columnchromatography (eluting solvent: chloroform:methanol=100:0 to 95:5) andsilica gel column chromatography (eluting solvent:chloroform:methanol=100:0 to 90:10). The resulting colorless solid waswashed with ethyl acetate to give the titled compound (1.00 g) as acolorless solid.

(2) Preparation of4-{[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}morpholine

A suspension of (2R)-1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidineobtained in Example 1-(2) (0.30 g),4-(1H-pyrazol-4-ylcarbonyl)morpholine obtained in Example 6-(1) (0.19g), (rac-trans-N,N′-dimethylcyclohexane-1,2-diamine (0.049 g), copperiodide (0.017 g) and cesium carbonate (0.57 g) in N,N-dimethylformamide(0.5 mL) was stirred at 120° C. for 1.5 hours. The reaction mixture wascooled to room temperature, diluted with water and extracted with ethylacetate. The organic layer was concentrated under reduced pressure, andthe resulting residue was purified by NH-type silica gel columnchromatography (eluting solvent: n-hexane:ethyl acetate=2:1 to 1:1). Theresulting crystal was washed with isopropyl ether to give the titledcompound (0.20 g) as a white solid.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.08 (d, J=6.0 Hz, 3H), 1.37-1.46(m, 1H), 1.64-1.82 (m, 2H), 1.87-2.05 (m, 3H), 2.11 (q, J=8.7 Hz, 1H),2.16-2.23 (m, 1H), 2.25-2.33 (m, 1H), 2.94-3.02 (m, 1H), 3.13-3.20 (m,1H), 3.67-3.81 (m, 8H), 4.01-4.10 (m, 2H), 6.94-7.01 (m, 2H), 7.52-7.58(m, 2H), 7.78 (s, 1H), 8.13 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 399 (M+H)⁺

Example 7 Preparation of4-{[1-(4-{3-[(2S)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}morpholine

The same procedure as shown in Example 6-(2) was repeated to give thetitled compound, except that(2R)-1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidine was replaced by(2S)-1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidine prepared in Example4-(1).

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.08 (d, J=6.0 Hz, 3H), 1.37-1.46(m, 1H), 1.64-1.82 (m, 2H), 1.87-2.05 (m, 3H), 2.11 (q, J=8.7 Hz, 1H),2.16-2.23 (m, 1H), 2.25-2.33 (m, 1H), 2.94-3.02 (m, 1H), 3.13-3.20 (m,1H), 3.67-3.81 (m, 8H), 4.01-4.10 (m, 2H), 6.94-7.01 (m, 2H), 7.52-7.58(m, 2H), 7.78 (s, 1H), 8.13 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 399 (M+H)⁺

Example 8 Preparation of4-({1-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-1H-pyrazol-4-yl}carbonyl)morpholine

The same procedures as shown in Example 1-(2) and Example 6-(2) wererepeated to give the titled compound, except that(R)-2-methylpyrrolidine was replaced by pyrrolidine.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.75-1.82 (m, 4H), 1.98-2.05 (m,2H), 2.49-2.56 (m, 4H), 2.59-2.67 (m, 2H), 3.67-3.81 (m, 8H), 4.06 (t,J=6.4 Hz, 2H), 6.94-7.01 (m, 2H), 7.52-7.58 (m, 2H), 7.77 (s, 1H), 8.13(s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 385 (M+H)⁺

Example 9 Preparation of4-({1-[4-(3-piperidin-1-ylpropoxy)phenyl]-1H-pyrazol-4-yl}carbonyl)morpholine

The same procedures as shown in Example 1-(2) and Example 6-(2) wererepeated to give the titled compound, except that(R)-2-methylpyrrolidine was replaced by piperidine.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.41-1.48 (m, 2H), 1.55-1.63 (m,4H), 1.96-2.03 (m, 2H), 2.34-2.50 (m, 6H), 3.70-3.80 (m, 8H), 4.05 (t,J=6.4 Hz, 2H), 6.98 (d, J=9.2 Hz, 2H), 7.56 (d, J=9.2 Hz, 2H), 7.78 (s,1H), 8.14 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 399 (M+H)⁺

Example 10 Preparation of4-[(1-{4-[3-(2,2-dimethylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)carbonyl]morpholine

The same procedures as shown in Example 1-(2) and Example 6-(2) wererepeated to give the titled compound, except that(R)-2-methylpyrrolidine was replaced by 2,2-dimethylpiperidine.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 0.97 (s, 6H), 1.60-1.66 (m, 2H),1.71-1.80 (m, 2H), 1.90-1.98 (m, 2H), 2.54 (t, J=7.1 Hz, 2H), 2.76 (t,J=7.3 Hz, 2H), 3.68-3.80 (m, 8H), 4.06 (t, J=6.4 Hz, 2H), 6.95-7.00 (m,2H), 7.53-7.58 (m, 2H), 7.78 (s, 1H), 8.13 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 413 (M+H)⁺

Example 11 Preparation ofN-tert-butyl-1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazole-4-carboxamide(1) Preparation of N-tert-butyl-1H-pyrazole-4-carboxamide

The same procedure as shown in Example 6-(1) was repeated to give thetitled compound, except that morpholine was replaced by2-methylpropane-2-amine.

(2) Preparation of 1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidine

The same procedure as shown in Example 1-(2) was repeated to give thetitled compound, except that (R)-2-methylpyrrolidine was replaced by2-methylpyrrolidine.

(3) Preparation ofN-tert-butyl-1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazole-4-carboxamide

The same procedure as shown in Example 1-(3) was repeated to give thetitled compound, except that(2R)-1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidine was replaced by1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidine obtained in Example11-(2), and 1H-pyrazole-4-carboxylic acid ethyl ester was replaced byN-tert-butyl-1H-pyrazole-4-carboxamide obtained in Example 11-(1).

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.11 (d, J=6.4 Hz, 3H), 1.47 (s,9H), 1.75-1.82 (m, 1H), 1.90-1.96 (m, 1H), 1.98-2.05 (m, 2H), 2.11-2.17(m, 1H), 2.20-2.25 (m, 1H), 2.29-2.36 (m, 1H), 2.96-3.02 (m, 1H),3.17-3.21 (m, 1H), 4.03-4.09 (m, 2H), 5.63 (br. s., 1H), 6.98 (d, J=9.2Hz, 2H), 7.55 (d, J=9.2 Hz, 2H), 7.82 (s, 1H), 8.21 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 385 (M+H)⁺

Example 12 Preparation ofN-tert-butyl-1-{4-[3-(2,5-dimethylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazole-4-carboxamide

The same procedures as shown in Example 11-(2) and Example 11-(3) wererepeated to give the titled compound, except that 2-methylpyrrolidinewas replaced by 2,5-dimethylpyrrolidine.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.11 (d, J=6.0 Hz, 6H), 1.33-1.41(m, 2H), 1.47 (s, 9H), 1.77-1.85 (m, 2H), 1.91-2.04 (m, 2H), 2.55-2.64(m, 2H), 2.73-2.77 (m, 2H), 4.04 (t, J=6.2 Hz, 2H), 5.61 (s, 1H), 6.97(d, J=8.7 Hz, 2H), 7.56 (d, J=9.2 Hz, 2H), 7.82 (s, 1H), 8.21 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 399 (M+H)⁺

Example 13 Preparation ofN-tert-butyl-1-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-1H-pyrazole-4-carboxamide

The same procedures as shown in Example 11-(2) and Example 11-(3) wererepeated to give the titled compound, except that 2-methylpyrrolidinewas replaced by pyrrolidine.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.46 (s, 9H), 1.76-1.81 (m, 4H),1.98-2.05 (m, 2H), 2.49-2.56 (m, 4H), 2.58-2.67 (m, 2H), 4.05 (t, J=6.6Hz, 2H), 5.60 (s, 1H), 6.92-7.01 (m, 2H), 7.50-7.58 (m, 2H), 7.81 (s,1H), 8.20 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 371 (M+H)⁺

Example 14 Preparation ofN-tert-butyl-1-{4-[3-(diethylamino)propoxy]phenyl}-1H-pyrazole-4-carboxamide

The same procedures as shown in Example 11-(2) and Example 11-(3) wererepeated to give the titled compound, except that 2-methylpyrrolidinewas replaced by diethylamine.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 2.55 (q, J=7.0 Hz, 4H), 2.59-2.63(m, 2H), 4.05 (t, J=6.4 Hz, 2H), 5.60 (s, 1H), 6.97 (d, 2H), 7.55 (d,J=9.2 Hz, 2H), 7.82 (s, 1H), 8.20 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 373 (M+H)⁺

Example 15 Preparation ofN-(4-fluorophenyl)-1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazole-4-carboxamide(1) Preparation of1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazole-4-carboxylicacid hydrochloride

The same procedures as shown in Example 1-(3) and Example 2-(1) wererepeated to give the titled compound, except that(2R)-1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidine was replaced by1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidine obtained in Example11-(2).

(2)N-(4-Fluorophenyl)-1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazole-4-carboxamide

The same procedure as shown in Example 2-(2) was repeated to give thetitled compound, except that1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxylicacid hydrochloride was replaced by1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazole-4-carboxylicacid hydrochloride obtained in Example 15-(1), and aqueous ammonia wasreplaced by 4-fluoroaniline.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.10 (d, J=6.0 Hz, 3H), 1.40-2.35(m, 9H), 2.97-3.03 (m, 1H), 3.17-3.23 (m, 1H), 4.05-4.12 (m, 2H),6.99-7.02 (m, 2H), 7.15-7.20 (m, 2H), 7.48 (s, 1H), 7.56-7.62 (m, 2H),8.00 (s, 1H), 8.37 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 423 (M+H)⁺

Example 16 Preparation ofN-(4-fluorophenyl)-1-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-1H-pyrazole-4-carboxamide

The same procedures as shown in Example 1-(2), Example 1-(3), Example2-(1) and Example 15-(2) were repeated to give the titled compound,except that 2-methylpyrrolidine was replaced by pyrrolidine.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.77-1.83 (m, 4H), 2.00-2.07 (m,2H), 2.52-2.58 (m, 4H), 2.66 (t, J=7.6 Hz, 2H), 4.07 (t, J=6.4 Hz, 2H),6.99 (d, J=9.2 Hz, 2H), 7.06 (t, J=8.5 Hz, 2H), 7.47 (s, 1H), 7.54-7.61(m, 2H), 7.58 (d, J=9.2 Hz, 2H), 8.00 (s, 1H), 8.37 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 409 (M+H)⁺

Example 17 Preparation ofN-(4-methylphenyl)-1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazole-4-carboxamide

The same procedure as shown in Example 15-(2) was repeated to give thetitled compound, except that 4-fluoroaniline was replaced by4-methylaniline.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.12 (br. s., 3H), 1.46 (br. s.,1H), 1.66-1.87 (m, 2H), 1.89-2.39 (m, 9H), 3.01 (br. s., 1H), 3.21 (br.s., 1H), 4.04-4.12 (m, 2H), 7.00 (d, J=9.2 Hz, 2H), 7.18 (d, J=8.3 Hz,2H), 7.42 (s, 1H), 7.49 (d, J=8.3 Hz, 2H), 7.60 (d, J=9.2 Hz, 2H), 7.99(br. s., 1H), 8.36 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 419 (M+H)⁺

Example 18 Preparation of1-{4-[3-(2-methylpyrrolidin-1-yl)-propoxy]-phenyl}-1H-pyrazole-4-carboxylicacid 4-fluorobenzylamide

The same procedure as shown in Example 15-(2) was repeated to give thetitled compound, except that 4-fluoroaniline was replaced by4-fluorobenzylamine.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.08 (d, J=6.0 Hz, 3H), 1.41 (dddd,J=12.5, 10.4, 8.7, 6.0 Hz, 1H), 1.65-1.72 (m, 1H), 1.73-1.82 (m, 1H),1.87-1.95 (m, 1H), 1.95-2.05 (m, 2H), 2.11 (q, J=9.2 Hz, 1H), 2.16-2.22(m, 1H), 2.25-2.32 (m, 1H), 2.94-3.01 (m, 1H), 3.14-3.20 (m, 1H),4.02-4.09 (m, 2H), 4.59 (d, J=6.0 Hz, 2H), 6.05-6.10 (m, 1H), 6.95-6.99(m, 2H), 7.01-7.06 (m, 2H), 7.30-7.35 (m, 2H), 7.55 (d, J=9.2 Hz, 2H),7.88 (s, 1H), 8.28 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 437 (M+H)⁺

Example 19 Preparation of1-{4-[3-(2-methylpyrrolidin-1-yl)-propoxy]-phenyl}-1H-pyrazole-4-carboxylicacid dimethylamide

The same procedure as shown in Example 15-(2) was repeated to give thetitled compound, except that 4-fluoroaniline was replaced bydimethylamine.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.08 (d, J=6.0 Hz, 3H), 1.37-1.45(m, 1H), 1.64-1.72 (m, 1H), 1.73-1.82 (m, 1H), 1.87-1.95 (m, 1H),1.95-2.06 (m, 2H), 2.11 (q, J=8.7 Hz, 1H), 2.16-2.23 (m, 1H), 2.25-2.33(m, 1H), 2.94-3.01 (m, 1H), 3.03-3.33 (m, 7H), 4.02-4.09 (m, 2H),6.94-7.01 (m, 2H), 7.54-7.59 (m, 2H), 7.86 (s, 1H), 8.17 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 357 (M+H)⁺

Example 20 Preparation of1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxylicacid bis-(2-hydroxyethyl)-amide

The same procedure as shown in Example 15-(2) was repeated to give thetitled compound, except that 4-fluoroaniline was replaced bydiethanolamine.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.09 (d, J=6.0 Hz, 3H), 1.37-1.47(m, 1H), 1.65-1.83 (m, 4H), 1.87-2.06 (m, 3H), 2.12 (q, J=9.0 Hz, 1H),2.16-2.23 (m, 1H), 2.26-2.36 (m, 1H), 2.94-3.02 (m, 1H), 3.13-3.21 (m,1H), 3.70 (br. s., 4H), 3.83-4.08 (m, 6H), 6.90-6.99 (m, 2H), 7.50-7.56(m, 2H), 7.99 (s, 1H), 8.32 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 417 (M+H)⁺

Example 21 Preparation ofazetidin-1-yl-(1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)methanone

The same procedure as shown in Example 15-(2) was repeated to give thetitled compound, except that 4-fluoroaniline was replaced bycyclobutylamine.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.08 (d, J=6.0 Hz, 3H), 1.37-1.45(m, 1H), 1.65-1.72 (m, 1H), 1.73-1.81 (m, 1H), 1.88-1.95 (m, 1H),1.95-2.05 (m, 2H), 2.10 (q, J=8.9 Hz, 1H), 2.17-2.22 (m, 1H), 2.25-2.32(m, 1H), 2.36-2.43 (m, 2H), 2.94-3.01 (m, 1H), 3.17 (td, J=8.6, 2.5 Hz,1H), 4.02-4.09 (m, 2H), 4.17-4.24 (m, 2H), 4.41-4.48 (m, 2H), 6.95-6.99(m, 2H), 7.54-7.58 (m, 2H), 7.85 (s, 1H), 8.22 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 369 (M+H)⁺

Example 22 Preparation of4-[(3,3-difluoropyrrolidin-1-yl)carbonyl]-1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole

The same procedure as shown in Example 2-(2) was repeated to give thetitled compound, except that aqueous ammonia was replaced by3,3-difluoropyrrolidine.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.10 (d, J=6.0 Hz, 3H), 1.38-1.48(m, 1H), 1.65-1.84 (m, 2H), 1.88-1.96 (m, 1H), 1.97-2.07 (m, 2H),2.09-2.16 (m, 1H), 2.17-2.25 (m, 1H), 2.27-2.35 (m, 1H), 2.39-2.56 (m,2H), 2.95-3.03 (m, 1H), 3.14-3.23 (m, 1H), 3.87-4.14 (m, 6H), 6.99 (d,J=9.2 Hz, 2H), 7.58 (d, J=9.2 Hz, 2H), 7.92 (br. s., 1H), 8.26 (br. s.,1H)

MS (ESI/APCI Dual) (Positive) m/z; 419 (M+H)⁺

Example 23 Preparation of(4-fluorophenyl)[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]methanone(1) Preparation of1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxylicacid methoxymethylamide

The same procedure as shown in Example 2-(2) was repeated to give thetitled compound, except that aqueous ammonia was replaced byN,O-dimethylhydroxylamine.

(2) Preparation of(4-fluorophenyl)[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]methanone

To a solution of1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxylicacid methoxymethylamide obtained in Example 23-(1) (0.25 g) intetrahydrofuran (3 mL), a solution of 4-fluorophenylmagnesium bromide intetrahydrofuran (1.0 M, 4.0 mL) was added dropwise in an ice bath andstirred at room temperature for 2 hours. The reaction mixture wasdiluted with saturated aqueous ammonium chloride and extracted withchloroform. The organic layer was dried over sodium sulfate andconcentrated under reduced pressure, and the resulting residue waspurified by NH-type silica gel column chromatography (eluting solvent:hexane:ethyl acetate=5:1 to 4:1) and silica gel column chromatography(eluting solvent: chloroform:methanol=95:5) to give the titled compound(0.11 g) as a light-blue solid.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.10 (d, J=6.0 Hz, 3H), 1.39-1.47(m, 1H), 1.64-1.84 (m, 2H), 1.90-1.96 (m, 1H), 1.99-2.06 (m, 2H),2.12-2.21 (m, 1H), 2.24 (s, 1H), 2.34 (s, 1H), 2.97-3.03 (m, 1H),3.17-3.23 (m, 1H), 4.04-4.10 (m, 2H), 7.00 (d, J=9.2 Hz, 2H), 7.17-7.22(m, 2H), 7.61 (d, J=9.2 Hz, 2H), 7.93 (dd, J=8.7, 5.5 Hz, 2H), 8.08 (s,1H), 8.34 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 408 (M+H)⁺

Example 24 Preparation of[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl](phenyl)methanone

The same procedure as shown in Example 23-(2) was repeated to give thetitled compound, except that 4-fluorophenylmagnesium bromide wasreplaced by phenylmagnesium bromide.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.09 (d, J=6.4 Hz, 3H), 1.38-1.45(m, 1H), 1.64-1.73 (m, 1H), 1.74-1.81 (m, 1H), 1.87-2.07 (m, 3H), 2.11(q, J=9.0 Hz, 1H), 2.18-2.23 (m, 1H), 2.27-2.32 (m, 1H), 2.96-3.01 (m,1H), 3.15-3.19 (m, 1H), 4.04-4.10 (m, 2H), 7.00 (d, J=9.2 Hz, 2H),7.49-7.53 (m, 2H), 7.57-7.63 (m, 3H), 7.89 (d, J=6.9 Hz, 2H), 8.11 (s,1H), 8.35 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 390 (M+H)⁺

Example 25 Preparation of(1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)(pyridin-2-yl)methanone(1) Preparation of (1H-pyrazol-4-yl)-pyridin-2-ylmethanone

To a solution of 4-iodopyrazole (1.0 g) in tetrahydrofuran (10 mL), asolution of n-butyllithium in hexane (2.6 M, 4.8 mL) was added dropwiseat −10° C. and stirred at room temperature for 1 hour. The reactionmixture was cooled to −10° C. and ethyl picolinate (0.86 g) was addedthereto, followed by stirring at room temperature for 1.5 hours. Thereaction mixture was diluted with saturated aqueous ammonium chlorideand extracted with diethyl ether. The organic layer was washed withbrine, dried over sodium sulfate and concentrated under reducedpressure. The resulting residue was purified by NH-type silica gelcolumn chromatography (eluting solvent: hexane:ethyl acetate=1:1 to 1:2)to give the titled compound (0.090 g) as a colorless solid.

(2) Preparation of(1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)(pyridin-2-yl)methanone

The same procedure as shown in Example 1-(3) was repeated to give thetitled compound, except that(2R)-1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidine was replaced by1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidine obtained in Example11-(2), and 1H-pyrazole-4-carboxylic acid ethyl ester was replaced by(1H-pyrazol-4-yl)-pyridin-2-ylmethanone obtained in Example 25-(1).

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.09 (d, J=6.4 Hz, 3H), 1.38-1.45(m, 1H), 1.63-1.72 (m, 1H), 1.74-1.82 (m, 1H), 1.89-1.96 (m, 1H),1.97-2.05 (m, 2H), 2.09-2.14 (m, 1H), 2.17-2.24 (m, 1H), 2.27-2.33 (m,1H), 2.94-3.01 (m, 1H), 3.16-3.20 (m, 1H), 4.04-4.10 (m, 2H), 7.00 (d,J=8.7 Hz, 2H), 7.48-7.51 (m, 1H), 7.65 (d, J=8.7 Hz, 2H), 7.87-7.91 (m,1H), 8.18-8.20 (m, 1H), 8.54 (s, 1H), 8.74-8.76 (m, 1H), 9.04 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 391 (M+H)⁺

Example 26 Preparation of[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl](pyridin-4-yl)methanone

The same procedures as shown in Example 25-(1) and Example 25-(2) wererepeated to give the titled compound, except that ethyl picolinate wasreplaced by ethyl isonicotinate, and1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidine was replaced by(2R)-1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidine obtained in Example1-(2).

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.08 (d, J=6.0 Hz, 3H), 1.38-1.44(m, 1H), 1.65-1.72 (m, 1H), 1.73-1.81 (m, 1H), 1.88-1.95 (m, 1H),1.96-2.05 (m, 2H), 2.11 (q, J=9.0 Hz, 1H), 2.17-2.23 (m, 1H), 2.26-2.32(m, 1H), 2.95-3.01 (m, 1H), 3.17 (td, J=8.5, 2.8 Hz, 1H), 4.04-4.10 (m,2H), 7.00 (d, J=9.2 Hz, 2H), 7.60 (d, J=9.2 Hz, 2H), 7.67 (d, J=6.0 Hz,2H), 8.10 (s, 1H), 8.35 (s, 1H), 8.83 (d, J=6.0 Hz, 2H)

MS (ESI/APCI Dual) (Positive) m/z; 391 (M+H)⁺

Example 27 Preparation of1-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]ethanone

The same procedure as shown in Example 23-(2) was repeated to give thetitled compound, except that 4-fluorophenylmagnesium bromide wasreplaced by methylmagnesium iodide.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.08 (d, J=6.0 Hz, 3H), 1.38-1.45(m, 1H), 1.64-1.72 (m, 1H), 1.74-1.81 (m, 1H), 1.88-1.94 (m, 1H),1.96-2.04 (m, 2H), 2.08-2.14 (m, 1H), 2.17-2.23 (m, 1H), 2.26-2.32 (m,1H), 2.48 (s, 3H), 2.95-3.00 (m, 1H), 3.15-3.19 (m, 1H), 4.03-4.09 (m,2H), 6.99 (d, J=9.2 Hz, 2H), 7.58 (d, J=9.2 Hz, 2H), 8.05 (s, 1H), 8.28(s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 328 (M+H)⁺

Example 28 Preparation of1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-4-nitro-1H-pyrazole

The same procedure as shown in Example 1-(3) was repeated to give thetitled compound, except that 1H-pyrazole-4-carboxylic acid ethyl esterwas replaced by 4-nitro-1H-pyrazole.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.08 (d, J=6.0 Hz, 3H), 1.36-1.47(m, 1H), 1.65-1.83 (m, 2H), 1.87-1.95 (m, 1H), 1.96-2.06 (m, 2H), 2.11(q, J=9.0 Hz, 1H), 2.16-2.24 (m, 1H), 2.25-2.33 (m, 1H), 2.91-3.03 (m,1H), 3.12-3.23 (m, 1H), 4.02-4.13 (m, 2H), 6.96-7.07 (m, 2H), 7.53-7.63(m, 2H), 8.23 (s, 1H), 8.51 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 331 (M+H)⁺

Example 29 Preparation of4-chloro-N-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]butylamide(1) Preparation of1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-ylamine

To a solution of1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-4-nitro-1H-pyrazoleobtained in Example 28 (0.67 g) in methanol (10 mL), 10% palladium oncarbon (0.067 g) was added and stirred under a hydrogen atmosphere atroom temperature for 4 hours. The reaction mixture was filtered throughcelite, and the filtrate was concentrated under reduced pressure. Theresulting residue was purified by NH-type silica gel columnchromatography (eluting solvent: hexane:ethyl acetate=3:1 to 1:1) togive the titled compound (0.258 g) as a yellow solid.

(2) Preparation of4-chloro-N-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]butylamide

To a solution of1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-ylamineobtained in Example 29-(1) (0.256 g) and pyridine (0.135 g) inchloroform (2.6 mL), 4-chlorobutyryl chloride (0.132 g) was added andstirred at room temperature for 30 minutes. The reaction mixture wasdiluted with saturated aqueous ammonium chloride and extracted withchloroform. The organic layer was washed with water and brine, driedover sodium sulfate and concentrated under reduced pressure to give thetitled compound (0.224 g) as a light-yellow solid.

1H NMR (600 MHz, DMSO-d₆) δ ppm 1.36 (d, J=6.4 Hz, 3H), 1.54-1.67 (m,1H), 1.82-2.21 (m, 6H), 2.30-2.52 (m, 3H), 2.97-3.13 (m, 2H), 3.33-3.45(m, 2H), 3.52-3.72 (m, 3H), 4.00-4.16 (m, 2H), 7.02 (d, J=9.2 Hz, 2H),7.54-7.74 (m, 3H), 8.42 (s, 1H), 10.19 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 405 (M+H)⁺

Example 30 Preparation of1-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]pyrrolidine-2-one

To a suspension of4-chloro-N-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]butylamideobtained in Example 29-(2) (0.224 g) in tetrahydrofuran (2.0 mL), sodiumhydride (55% in mineral oil, 0.111 g) was added and stirred at roomtemperature for 30 minutes. The reaction mixture was diluted with waterand extracted with chloroform. The organic layer was washed with brine,dried over sodium sulfate and concentrated under reduced pressure. Theresulting residue was purified by NH-type silica gel columnchromatography (eluting solvent: chloroform:methanol=100:1), and theresulting crystal was washed with diisopropyl ether to give the titledcompound (0.127 g) as a light-yellow solid.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.09 (d, J=6.4 Hz, 3H), 1.36-1.46(m, 1H), 1.64-1.84 (m, 2H), 1.87-2.07 (m, 3H), 2.07-2.16 (m, 1H),2.16-2.33 (m, 4H), 2.57 (t, J=8.0 Hz, 2H), 2.94-3.02 (m, 1H), 3.13-3.22(m, 1H), 3.80 (t, J=7.3 Hz, 2H), 4.00-4.09 (m, 2H), 6.92-6.99 (m, 2H),7.54-7.61 (m, 2H), 7.65 (s, 1H), 8.43 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 369 (M+H)⁺

Example 31 Preparation of1-[1-(4-{3-[(2S)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]pyrrolidine-2-one

The same procedures as shown in Example 28, Example 29-(1), Example29-(2) and Example 30 were repeated to give the titled compound, exceptthat (2R)-1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidine was replacedby (2S)-1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidine obtained inExample 4-(1).

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.09 (d, J=6.4 Hz, 3H), 1.36-1.46(m, 1H), 1.64-1.84 (m, 2H), 1.87-2.07 (m, 3H), 2.07-2.16 (m, 1H),2.16-2.33 (m, 4H), 2.57 (t, J=8.0 Hz, 2H), 2.94-3.02 (m, 1H), 3.13-3.22(m, 1H), 3.80 (t, J=7.3 Hz, 2H), 4.00-4.09 (m, 2H), 6.92-6.99 (m, 2H),7.54-7.61 (m, 2H), 7.65 (s, 1H), 8.43 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 369 (M+H)⁺

Example 32 Preparation of1-{1-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-1H-pyrazol-4-yl}pyrrolidine-2-one

The same procedures as shown in Example 1-(2), Example 28, Example29-(1), Example 29-(2) and Example 30 were repeated to give the titledcompound, except that 2-methylpyrrolidine was replaced by pyrrolidine.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.72-1.82 (m, 4H), 2.02 (q, J=6.9Hz, 2H), 2.19-2.28 (m, 2H), 2.47-2.66 (m, 8H), 3.76-3.84 (m, 2H), 4.06(t, J=6.4 Hz, 2H), 6.96 (d, J=9.2 Hz, 2H), 7.58 (d, J=9.2 Hz, 2H), 7.65(s, 1H), 8.44 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 355 (M+H)⁺

Example 33 Preparation of(1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)carbamicacid 2-chloroethyl ester

The same procedure as shown in Example 29-(2) was repeated to give thetitled compound, except that 4-chlorobutyryl chloride was replaced by2-chloroethyl chloroformate.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.91-2.38 (m, 7H), 2.49-3.51 (m,4H), 3.67-3.97 (m, 4H), 4.02-4.16 (m, 2H), 4.36-4.51 (m, 3H), 6.70 (s,1H), 6.87-6.97 (m, 2H), 7.51-7.61 (m, 3H), 8.09 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 407 (M+H)⁺

Example 34 Preparation of3-(1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)-1,3-oxazolidin-2-one

The same procedure as shown in Example 30 was repeated to give thetitled compound, except that4-chloro-N-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]butylamidewas replaced by(1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)carbamicacid 2-chloroethyl ester obtained in Example 33.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.08 (d, J=6.0 Hz, 3H), 1.37-1.45(m, 1H), 1.64-1.82 (m, 2H), 1.87-2.05 (m, 3H), 2.11 (q, J=8.9 Hz, 1H),2.16-2.23 (m, 1H), 2.25-2.32 (m, 1H), 2.94-3.01 (m, 1H), 3.14-3.20 (m,1H), 3.97-4.08 (m, 4H), 4.52-4.57 (m, 2H), 6.93-6.98 (m, 2H), 7.54-7.57(m, 2H), 7.59 (s, 1H), 8.18 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 371 (M+H)⁺

Example 35 Preparation of 5-chloropentanoyl acid(1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)amide

The same procedure as shown in Example 29-(2) was repeated to give thetitled compound, except that 4-chlorobutyryl chloride was replaced by5-chlorovaleryl chloride.

1H NMR (600 MHz, DMSO-d₆) δ ppm 1.28-1.42 (m, 3H), 1.54-1.79 (m, 5H),1.83-2.32 (m, 7H), 3.06 (br. s., 2H), 3.24-3.48 (m, 2H), 3.54-3.68 (m,3H), 4.04 (br. s., 2H), 7.01 (d, J=9.2 Hz, 2H), 7.60-7.74 (m, 3H), 8.39(s, 1H), 10.09 (s, 1H)

MS (ESI) (Positive) m/z; 419 (M+H)⁺

Example 36 Preparation of1-(1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)piperidin-2-one

The same procedure as shown in Example 30 was repeated to give thetitled compound, except that4-chloro-N-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]butylamidewas replaced by 5-chloropentanoyl acid(1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)amideobtained in Example 35.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.08 (d, J=6.0 Hz, 3H), 1.36-1.45(m, 1H), 1.63-1.82 (m, 2H), 1.85-2.05 (m, 7H), 2.10 (q, J=8.9 Hz, 1H),2.16-2.22 (m, 1H), 2.24-2.32 (m, 1H), 2.58 (t, J=6.6 Hz, 2H), 2.94-3.01(m, 1H), 3.14-3.20 (m, 1H), 3.72 (t, J=6.2 Hz, 2H), 4.00-4.08 (m, 2H),6.95 (d, J=8.7 Hz, 2H), 7.54-7.59 (m, 2H), 7.70 (s, 1H), 8.49 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 383 (M+H)⁺

Example 37 Preparation ofN-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]acetamide

The same procedure as shown in Example 29-(2) was repeated to give thetitled compound, except that 4-chlorobutyryl chloride was replaced byacetyl chloride.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.09 (d, J=6.0 Hz, 3H), 1.38-1.47(m, 1H), 1.64-1.73 (m, 1H), 1.74-1.83 (m, 1H), 1.88-2.06 (m, 3H), 2.12(q, J=8.9 Hz, 1H), 2.15-2.24 (m, 4H), 2.26-2.33 (m, 1H), 2.95-3.02 (m,1H), 3.18 (td, J=8.6, 2.5 Hz, 1H), 4.01-4.09 (m, 2H), 6.96 (d, J=9.2 Hz,2H), 7.18 (s, 1H), 7.55 (d, J=2.3 Hz, 2H), 7.57 (s, 1H), 8.37 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 343 (M+H)⁺

Example 38 Preparation ofN-methyl-N-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]acetamide

To a solution ofN-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]acetamideobtained in Example 37 (0.34 g) in tetrahydrofuran (3.5 mL), sodiumhydride (55% in mineral oil, 0.048 g) was added and iodomethane (0.225g) was then added dropwise under ice cooling, followed by stirring atroom temperature for 1.5 hours. The reaction mixture was diluted withwater and extracted with ethyl acetate. The organic layer was washedwith water and brine, dried over sodium sulfate and concentrated underreduced pressure. The resulting residue was purified by NH-type silicagel column chromatography (eluting solvent: ethylacetate:hexane=1:1→ethyl acetate), and the resulting crystal was washedwith diisopropyl ether to give the titled compound (0.187 g) as a whitesolid.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.08 (d, J=6.0 Hz, 3H), 1.37-1.47(m, 1H), 1.60-1.83 (m, 2H), 1.86-2.07 (m, 5H), 2.07-2.15 (m, 1H),2.16-2.24 (m, 1H), 2.25-2.34 (m, 2H), 2.93-3.03 (m, 1H), 3.14-3.21 (m,1H), 3.24 (s, 2H), 3.40 (s, 1H), 4.00-4.10 (m, 2H), 6.92-7.01 (m, 2H),7.50-7.60 (m, 8/3H), 7.66 (s, ⅓H), 7.77 (s, ⅔H), 8.42 (s, ⅓H)

MS (ESI/APCI Dual) (Positive) m/z; 357 (M+H)⁺

Example 39 Preparation ofN-ethyl-N-(1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)acetamide

The same procedure as shown in Example 38 was repeated to give thetitled compound, except that iodomethane was replaced by iodoethane.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.10 (d, J=6.0 Hz, 3H), 1.15 (t,J=7.1 Hz, 3H.⅚), 1.24-1.32 (m, 1H), 1.34 (t, J=7.3 Hz, 3H.⅙), 1.38-1.46(m, 1H), 1.66-1.74 (m, 1H), 1.74-1.83 (m, 1H), 1.89-2.34 (m, 8H), 2.30(s, 1H), 2.96-3.03 (m, 1H), 3.19 (td, J=8.6, 2.5 Hz, 1H), 3.69 (q, J=6.9Hz, 2H.⅚), 3.78 (q, J=7.0 Hz, 2H.⅙), 4.03-4.11 (m, 2H), 6.95-7.01 (m,2H), 7.54-7.65 (m, 3H), 7.77 (s, 1H.⅚), 8.41 (s, 1H.⅙)

MS (ESI/APCI Dual) (Positive) m/z; 371 (M+H)⁺

Example 40 Preparation of4-cyano-N-(1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)benzamide

The same procedure as shown in Example 29-(2) was repeated to give thetitled compound, except that 4-chlorobutyryl chloride was replaced by4-cyanobenzoyl chloride.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.10 (d, J=6.0 Hz, 3H), 1.38-1.47(m, 1H), 1.66-1.74 (m, 1H), 1.74-1.83 (m, 1H), 1.89-2.06 (m, 3H), 2.12(q, J=8.7 Hz, 1H), 2.19-2.24 (m, 1H), 2.27-2.33 (m, 1H), 2.96-3.02 (m,1H), 3.18 (td, J=8.7, 2.8 Hz, 1H), 4.03-4.11 (m, 2H), 6.99 (d, J=9.2 Hz,2H), 7.60 (d, J=9.2 Hz, 2H), 7.72 (s, 1H), 7.81 (d, J=8.3 Hz, 2H), 7.92(s, 1H), 7.99 (d, J=8.7 Hz, 2H), 8.55 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 430 (M+H)⁺

Example 41 Preparation of4-methoxy-N-(1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)benzamide

The same procedure as shown in Example 29-(2) was repeated to give thetitled compound, except that 4-chlorobutyryl chloride was replaced by4-methoxybenzoyl chloride.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.10 (d, J=6.0 Hz, 3H), 1.39-1.46(m, 1H), 1.65-1.82 (m, 2H), 1.89-2.06 (m, 3H), 2.12 (q, J=8.7 Hz, 1H),2.18-2.24 (m, 1H), 2.27-2.33 (m, 1H), 2.96-3.02 (m, 1H), 3.19 (td,J=8.6, 2.5 Hz, 1H), 3.88 (s, 3H), 4.03-4.10 (m, 2H), 6.96-7.01 (m, 4H),7.60 (d, J=9.2 Hz, 2H), 7.69 (s, 1H), 7.74 (s, 1H), 7.85 (d, J=8.7 Hz,2H), 8.55 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 435 (M+H)⁺

Example 42 Preparation of4-hydroxy-N-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]benzamide

A suspension of1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-ylamineobtained in Example 29-(1) (0.191 g), 4-hydroxybenzoic acid (0.097 g),1-hydroxybenzotriazole monohydrate (0.107 g) and3-(3-dimethylaminopropyl)-1-ethylcarbodiimide hydrochloride (0.18 g) inchloroform (6.4 mL) was stirred at room temperature for 4 days. Thereaction mixture was concentrated under reduced pressure, and theresidue was purified by NH-type silica gel column chromatography(eluting solvent: chloroform→chloroform:methanol=10:1) to give thetitled compound (0.137 g) as a colorless amorphous substance.

1H NMR (600 MHz, DMSO-d₆) δ ppm 1.00 (d, J=6.0 Hz, 3H), 1.24-1.32 (m,1H), 1.58-1.70 (m, 2H), 1.80-1.95 (m, 3H), 2.04 (q, J=8.7 Hz, 1H),2.09-2.15 (m, 1H), 2.20-2.29 (m, 1H), 2.87-2.96 (m, 1H), 3.08 (td,J=8.4, 3.0 Hz, 1H), 4.05 (t, J=6.2 Hz, 2H), 6.87 (d, J=8.7 Hz, 2H), 7.03(d, J=8.7 Hz, 2H), 7.68 (d, J=9.2 Hz, 2H), 7.83 (s, 1H), 7.86 (d, J=8.7Hz, 2H), 8.53 (s, 1H), 10.14 (br. s., 1H), 10.32 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 421 (M+H)⁺

Example 43 Preparation ofN-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]pyridine-3-carboxamide

The same procedure as shown in Example 29-(2) was repeated to give thetitled compound, except that 4-chlorobutyryl chloride was replaced bynicotinoyl chloride hydrochloride.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.09 (d, J=6.0 Hz, 3H), 1.37-1.47(m, 1H), 1.65-1.83 (m, 2H), 1.87-2.06 (m, 3H), 2.11 (q, J=9.0 Hz, 1H),2.17-2.24 (m, 1H), 2.25-2.33 (m, 1H), 2.94-3.02 (m, 1H), 3.14-3.21 (m,1H), 4.02-4.10 (m, 2H), 6.95-7.00 (m, 2H), 7.43-7.48 (m, 1H), 7.56-7.62(m, 2H), 7.73 (s, 1H), 7.96 (s, 1H), 8.19-8.23 (m, 1H), 8.54 (s, 1H),8.76-8.80 (m, 1H), 9.08-9.12 (m, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 406 (M+H)⁺

Example 44 Preparation ofN-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]pyridine-4-carboxamide

The same procedure as shown in Example 29-(2) was repeated to give thetitled compound, except that 4-chlorobutyryl chloride was replaced byisonicotinoyl chloride hydrochloride.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.09 (d, J=6.4 Hz, 3H), 1.38-1.46(m, 1H), 1.65-1.82 (m, 2H), 1.87-2.06 (m, 3H), 2.11 (q, J=8.7 Hz, 1H),2.17-2.23 (m, 1H), 2.26-2.33 (m, 1H), 2.95-3.01 (m, 1H), 3.15-3.20 (m,1H), 4.02-4.09 (m, 2H), 6.95-6.99 (m, 2H), 7.56-7.60 (m, 2H), 7.71 (d,J=4.6 Hz, 3H), 8.02 (s, 1H), 8.54 (s, 1H), 8.77-8.84 (m, 2H)

MS (ESI/APCI Dual) (Positive) m/z; 406 (M+H)⁺

Example 45 Preparation of2-(4-hydroxyphenyl)-N-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]acetamide

The same procedure as shown in Example 42 was repeated to give thetitled compound, except that 4-hydroxybenzoic acid was replaced by4-hydroxyphenylacetic acid.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.11 (d, J=6.0 Hz, 3H), 1.44 (dddd,J=17.0, 4.0, 2.5, 2.2 Hz, 1H), 1.66-1.75 (m, 1H), 1.75-1.84 (m, 1H),1.88-2.03 (m, 3H), 2.11-2.25 (m, 2H), 2.29-2.38 (m, 1H), 2.97-3.05 (m,1H), 3.15-3.21 (m, 1H), 3.63 (s, 2H), 4.02 (t, J=6.9 Hz, 2H), 6.77-6.82(m, 2H), 6.86-6.92 (m, 2H), 7.12 (d, J=8.7 Hz, 2H), 7.34 (s, 1H),7.43-7.51 (m, 3H), 8.32 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 435 (M+H)⁺

Example 46 Preparation ofN-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]-2-(pyridin-3-yl)acetamide

The same procedure as shown in Example 42 was repeated to give thetitled compound, except that 4-hydroxybenzoic acid was replaced by3-pyridylacetic acid.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.08 (d, J=6.0 Hz, 3H), 1.36-1.46(m, 1H), 1.63-1.82 (m, 2H), 1.86-2.05 (m, 3H), 2.10 (q, J=9.2 Hz, 1H),2.15-2.22 (m, 1H), 2.24-2.33 (m, 1H), 2.92-3.02 (m, 1H), 3.13-3.20 (m,1H), 3.72 (s, 2H), 3.99-4.08 (m, 2H), 6.91-6.98 (m, 2H), 7.30-7.41 (m,2H), 7.49-7.57 (m, 3H), 7.72 (d, J=7.8 Hz, 1H), 8.36 (s, 1H), 8.53-8.61(m, 2H)

MS (ESI/APCI Dual) (Positive) m/z; 420 (M+H)⁺

Example 47 Preparation ofN-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]-2-(pyridin-4-yl)acetamide

The same procedure as shown in Example 42 was repeated to give thetitled compound, except that 4-hydroxybenzoic acid was replaced by4-pyridylacetic acid.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.08 (d, J=6.0 Hz, 3H), 1.37-1.45(m, 1H), 1.65-1.72 (m, 1H), 1.72-1.81 (m, 1H), 1.86-2.04 (m, 3H), 2.10(q, J=8.7 Hz, 1H), 2.15-2.22 (m, 1H), 2.24-2.32 (m, 1H), 2.93-3.00 (m,1H), 3.13-3.19 (m, 1H), 3.71 (s, 2H), 3.99-4.07 (m, 2H), 6.91-6.96 (m,2H), 7.28 (d, J=6.0 Hz, 2H), 7.39 (s, 1H), 7.50-7.55 (m, 3H), 8.36 (s,1H), 8.59-8.62 (m, 2H)

MS (ESI/APCI Dual) (Positive) m/z; 420 (M+H)⁺

Example 48 Preparation ofN-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]methanesulfonamide

The same procedure as shown in Example 29-(2) was repeated to give thetitled compound, except that 4-chlorobutyryl chloride was replaced bymethanesulfonyl chloride.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.09 (d, J=6.4 Hz, 3H), 1.38-1.47(m, 1H), 1.64-1.83 (m, 2H), 1.87-2.06 (m, 3H), 2.07-2.34 (m, 3H),2.95-3.02 (m, 4H), 3.14-3.21 (m, 1H), 4.02-4.08 (m, 2H), 6.94-6.98 (m,2H), 7.51-7.55 (m, 2H), 7.59-7.61 (m, 1H), 7.92-7.94 (m, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 379 (M+H)⁺

Example 49 Preparation ofN-methyl-N-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]methanesulfonamide

The same procedure as shown in Example 38 was repeated to give thetitled compound, except thatN-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]acetamidewas replaced byN-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]methanesulfonamideobtained in Example 48.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.08 (d, J=6.0 Hz, 3H), 1.37-1.45(m, 1H), 1.64-1.82 (m, 2H), 1.87-2.03 (m, 3H), 2.11 (q, J=9.0 Hz, 1H),2.17-2.23 (m, 1H), 2.25-2.33 (m, 1H), 2.83 (s, 3H), 2.94-3.01 (m, 1H),3.14-3.20 (m, 1H), 3.30 (s, 3H), 4.01-4.09 (m, 2H), 6.94-6.99 (m, 2H),7.51-7.56 (m, 2H), 7.65 (s, 1H), 7.91 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 393 (M+H)⁺

Example 50 Preparation of4-cyano-N-(1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)benzenesulfonamide

The same procedure as shown in Example 29-(2) was repeated to give thetitled compound, except that 4-chlorobutyryl chloride was replaced by4-cyanobenzenesulfonyl chloride.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.17 (d, J=6.0 Hz, 3H), 1.49-1.57(m, 1H), 1.73-1.81 (m, 1H), 1.84-1.93 (m, 1H), 1.96-2.12 (m, 3H),2.31-2.41 (m, 2H), 2.50-2.58 (m, 1H), 3.02-3.09 (m, 1H), 3.31 (td,J=8.9, 3.2 Hz, 1H), 4.00 (t, J=6.4 Hz, 2H), 5.55 (br. s., 1H), 6.88 (d,J=8.7 Hz, 2H), 7.31 (s, 1H), 7.43 (d, J=9.2 Hz, 2H), 7.72 (d, J=8.7 Hz,2H), 7.76 (s, 1H), 7.88 (d, J=8.7 Hz, 2H)

MS (ESI/APCI Dual) (Positive) m/z; 466 (M+H)⁺

Example 51 Preparation ofN-[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]pyridine-3-sulfonamide

The same procedure as shown in Example 29-(2) was repeated to give thetitled compound, except that 4-chlorobutyryl chloride was replaced bypyridine-3-sulfonyl chloride.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.10 (d, J=6.0 Hz, 3H), 1.40-1.48(m, 1H), 1.67-1.74 (m, 1H), 1.76-1.85 (m, 1H), 1.89-2.06 (m, 3H), 2.16(q, J=8.7 Hz, 1H), 2.20-2.27 (m, 1H), 2.31-2.38 (m, 1H), 2.99 (dd,J=8.3, 4.1 Hz, 1H), 3.17-3.23 (m, 1H), 3.99-4.06 (m, 2H), 6.90-6.95 (m,2H), 7.32 (s, 1H), 7.41 (dd, J=8.0, 4.8 Hz, 1H), 7.44-7.48 (m, 2H), 7.80(s, 1H), 8.00-8.04 (m, 1H), 8.76-8.79 (m, 1H), 9.01 (d, J=1.8 Hz, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 442 (M+H)⁺

Example 52 Preparation of1-(1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)pyrrolidine-2,5-dione

A solution of1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-ylamineobtained in the same manner as shown in Example 29-(1) (0.186 g) andsuccinic anhydride (0.074 g) in toluene (12 mL) was stirred underheating at reflux for 4 hours. The reaction mixture was cooled in an icebath, and the precipitated crystal was collected by filtration andwashed with toluene to giveN-(1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)succinamicacid (0.191 g) as a colorless powder. A suspension ofN-(1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)succinamicacid thus obtained (0.108 g) in acetic anhydride (5.4 mL) was stirredunder heating at reflux for 30 minutes. The reaction mixture was cooledto room temperature, diluted with saturated aqueous sodium bicarbonateand extracted with chloroform. The organic layer was dried over sodiumsulfate and concentrated under reduced pressure, and the resultingresidue was purified by NH-type silica gel column chromatography(eluting solvent: hexane:ethyl acetate=1:1). The resulting solid waswashed with diisopropyl ether to give the titled compound (0.044 g) as acolorless powder.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.10 (d, J=6.4 Hz, 3H), 1.38-1.47(m, 1H), 1.65-1.73 (m, 1H), 1.74-1.83 (m, 1H), 1.88-2.06 (m, 3H), 2.12(q, J=8.7 Hz, 1H), 2.17-2.24 (m, 1H), 2.26-2.34 (m, 1H), 2.89 (s, 4H),2.95-3.03 (m, 1H), 3.18 (td, J=8.7, 2.8 Hz, 1H), 4.03-4.10 (m, 2H), 6.98(d, J=8.7 Hz, 2H), 7.60 (d, J=8.7 Hz, 2H), 8.32 (s, 1H), 8.53 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 383 (M+H)⁺

Example 53 Preparation of(2,6-dimethylmorpholin-4-yl)[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]methanone

The same procedure as shown in Example 2-(2) was repeated to give thetitled compound, except that aqueous ammonia was replaced bycis-2,6-dimethylmorpholine.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.09 (d, J=6.0 Hz, 3H), 1.22 (br.s., 6H), 1.38-1.46 (m, 1H), 1.63-1.84 (m, 3H), 1.87-2.06 (m, 3H), 2.12(q, J=8.9 Hz, 1H), 2.17-2.25 (m, 1H), 2.25-2.34 (m, 1H), 2.55 (br. s.,1H), 2.81-3.05 (m, 2H), 3.18 (td, J=8.7, 2.8 Hz, 1H), 3.62 (br. s., 2H),4.00-4.11 (m, 2H), 4.53 (br. s., 1H), 6.99 (d, J=8.7 Hz, 2H), 7.57 (d,J=8.7 Hz, 2H), 7.77 (s, 1H), 8.13 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 427 (M+H)⁺

Example 54 Preparation of[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl](1,4-oxazepan-4-yl)methanone

The same procedure as shown in Example 2-(2) was repeated to give thetitled compound, except that aqueous ammonia was replaced byhomomorpholine.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.09 (d, J=6.0 Hz, 3H), 1.37-1.47(m, 1H), 1.65-1.73 (m, 1H), 1.73-1.83 (m, 1H), 1.87-1.95 (m, 1H),1.96-2.06 (m, 4H), 2.07-2.15 (m, 1H), 2.16-2.24 (m, 1H), 2.25-2.33 (m,1H), 2.95-3.02 (m, 1H), 3.14-3.21 (m, 1H), 3.76-3.89 (m, 8H), 4.02-4.09(m, 2H), 6.98 (d, J=9.2 Hz, 2H), 7.56 (d, J=8.7 Hz, 2H), 7.75-7.86 (m,1H), 8.13-8.21 (m, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 413 (M+H)⁺

Example 55 Preparation of(4-methylpiperazin-1-yl)[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]methanone

The same procedure as shown in Example 2-(2) was repeated to give thetitled compound, except that aqueous ammonia was replaced by4-methylpiperazine.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.10 (d, J=6.0 Hz, 3H), 1.37-1.48(m, 1H), 1.62-2.07 (m, 5H), 2.08-2.16 (m, 1H), 2.17-2.25 (m, 1H),2.26-2.37 (m, 4H), 2.46 (br. s., 4H), 2.95-3.03 (m, 1H), 3.15-3.22 (m,1H), 3.78 (br. s., 4H), 4.02-4.11 (m, 2H), 6.98 (d, J=9.2 Hz, 2H), 7.57(d, J=8.7 Hz, 2H), 7.79 (s, 1H), 8.13 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 412 (M+H)⁺

Example 56 Preparation of[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl](pyrrolidin-1-yl)methanone

The same procedure as shown in Example 2-(2) was repeated to give thetitled compound, except that aqueous ammonia was replaced bypyrrolidine.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.10 (d, J=6.0 Hz, 3H), 1.38-1.47(m, 1H), 1.64-2.07 (m, 9H), 2.09-2.15 (m, 1H), 2.17-2.24 (m, 1H),2.26-2.34 (m, 1H), 2.95-3.03 (m, 1H), 3.15-3.22 (m, 1H), 3.66 (t, J=6.9Hz, 2H), 3.75 (t, J=6.6 Hz, 2H), 4.02-4.11 (m, 2H), 6.96-7.01 (m, 2H),7.56-7.61 (m, 2H), 7.96 (s, 1H), 8.28 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 383 (M+H)⁺

Example 57 Preparation of(1-{4-[3-(3-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)(morpholin-4-yl)methanone

The same procedures as shown in Example 1-(2) and Example 6-(2) wererepeated to give the titled compound, except that(R)-2-methylpyrrolidine was replaced by 3-methylpyrrolidine.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.04 (d, J=6.9 Hz, 3H), 1.31-1.40(m, 1H), 1.97-2.07 (m, 4H), 2.22-2.31 (m, 1H), 2.44-2.50 (m, 1H),2.55-2.61 (m, 1H), 2.62-2.68 (m, 1H), 2.69-2.76 (m, 1H), 2.83-2.89 (m,1H), 3.71-3.81 (m, 8H), 4.06 (t, J=6.4 Hz, 2H), 6.95-7.01 (m, 2H),7.53-7.59 (m, 2H), 7.78 (s, 1H), 8.14 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 399 (M+H)⁺

Example 58 Preparation of(1-{4-[3-(2-ethylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)(morpholin-4-yl)methanone

The same procedures as shown in Example 1-(2) and Example 6-(2) wererepeated to give the titled compound, except that(R)-2-methylpyrrolidine was replaced by 2-ethylpyrrolidine.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 0.87 (t, J=7.3 Hz, 3H), 1.16-1.29(m, 1H), 1.39-1.49 (m, 1H), 1.67-1.82 (m, 3H), 1.87-1.95 (m, 1H),1.95-2.06 (m, 2H), 2.08-2.14 (m, 1H), 2.13-2.19 (m, 1H), 2.19-2.27 (m,1H), 2.90-3.07 (m, 1H), 3.11-3.26 (m, 1H), 3.68-3.85 (m, 8H), 3.93-4.13(m, 2H), 6.93-7.05 (m, 2H), 7.49-7.61 (m, 2H), 7.78 (s, 1H), 8.14 (s,1H)

MS (ESI/APCI Dual) (Positive) m/z; 413 (M+H)⁺

Example 59 Preparation of(1-{4-[3-(2,2-difluoropyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazol-4-yl)(morpholin-4-yl)methanone

The same procedures as shown in Example 1-(2) and Example 6-(2) wererepeated to give the titled compound, except that(R)-2-methylpyrrolidine was replaced by 2,2-difluoropyrrolidine.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.94-2.03 (m, 2H), 2.23-2.34 (m,2H), 2.66 (t, J=7.1 Hz, 2H), 2.76 (t, J=7.1 Hz, 2H), 2.93 (t, J=13.3 Hz,2H), 3.68-3.83 (m, 8H), 4.07 (t, J=6.2 Hz, 2H), 6.94-7.02 (m, 2H),7.54-7.60 (m, 2H), 7.79 (s, 1H), 8.15 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 421 (M+H)⁺

Example 60 Preparation of[1-(4-{2-[(2R)-2-methylpyrrolidin-1-yl]ethoxy}phenyl)-1H-pyrazol-4-yl](morpholin-4-yl)methanone(1) Preparation of 1-(2-chloroethoxy)-4-iodobenzene

To a solution of 4-iodophenol (1.0 g) in acetonitrile (10 mL), cesiumcarbonate (3.0 g) and 1-bromo-2-chloroethane (0.8 g) were added and themixture was heated to 100° C., at which it was stirred for 4 hours.Additional 1-bromo-2-chloroethane (1.0 g) was further added and stirredat 100° C. for 4 hours. The reaction mixture was cooled to roomtemperature and filtered to remove insoluble materials, and the filtratewas concentrated under reduced pressure. The resulting residue waspurified by NH-type silica gel column chromatography (eluting solvent:n-hexane:ethyl acetate=11:1) to give the titled compound (0.87 g, 68%)as a yellow oil.

(2) Preparation of (2R)-1-[2-(4-iodophenoxy)ethyl]-2-methylpyrrolidine

To a suspension of (2R)-2-methylpyrrolidine (0.60 g) and cesiumcarbonate (1.2 g) in acetonitrile (3 mL),1-(2-chloroethoxy)-4-iodobenzene obtained in Example 60-(1) (0.87 g) wasadded and the mixture was heated to 100° C., at which it was stirred for9 hours. The reaction mixture was cooled to room temperature andfiltered to remove insoluble materials, and the filtrate wasconcentrated under reduced pressure. The resulting residue was purifiedby NH-type silica gel column chromatography (eluting solvent:n-hexane:ethyl acetate=9:1 to 1:1) to give the titled compound (0.80 g,78%) as a colorless oil.

(3) Preparation of[1-(4-{2-[(2R)-2-methylpyrrolidin-1-yl]ethoxy}phenyl)-1H-pyrazol-4-yl](morpholin-4-yl)methanone

The same procedure as shown in Example 6 was repeated to give the titledcompound, except that(2R)-1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidine was replaced by(2R)-1-[2-(4-iodophenoxy)ethyl]-2-methylpyrrolidine obtained in Example60-(2).

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.15 (d, J=6.0 Hz, 3H), 1.41-1.51(m, 1H), 1.69-1.77 (m, 1H), 1.78-1.88 (m, 1H), 1.90-1.98 (m, 1H),2.25-2.33 (m, 1H), 2.39-2.46 (m, 1H), 2.52-2.60 (m, 1H), 3.18-3.30 (m,2H), 3.70-3.81 (m, 8H), 4.09-4.19 (m, 2H), 6.97-7.03 (m, 2H), 7.54-7.60(m, 2H), 7.79 (s, 1H), 8.14 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 385 (M+H)⁺

Example 61 Preparation of[1-(4-{4-[(2R)-2-methylpyrrolidin-1-yl]butoxy}phenyl)-1H-pyrazol-4-yl](morpholin-4-yl)methanone(1) Preparation of 1-(4-chlorobutoxy)-4-iodobenzene

To a solution of 4-iodophenol (1.0 g) in acetonitrile (10 mL), cesiumcarbonate (3.0 g) and 1-chloro-4-iodobutane (1.2 g) were added and themixture was heated to 100° C., at which it was stirred for 4 hours. Thereaction mixture was cooled to room temperature and filtered to removeinsoluble materials, and the filtrate was concentrated under reducedpressure. The resulting residue was purified by NH-type silica gelcolumn chromatography (eluting solvent: n-hexane:ethyl acetate=7:3 to1:1) to give the titled compound (1.4 g, 99%) as a brown oil.

(2) Preparation of (2R)-1-[4-(4-iodophenoxy)butyl]-2-methylpyrrolidine

To a suspension of (2R)-2-methylpyrrolidine (0.8 g) and cesium carbonate(1.7 g) in acetonitrile (5 mL), 1-(4-chlorobutoxy)-4-iodobenzeneobtained in Example 61-(1) (1.4 g) was added and the mixture was heatedto 100° C., at which it was stirred for 9 hours. The reaction mixturewas cooled to room temperature and filtered to remove insolublematerials, and the filtrate was concentrated under reduced pressure. Theresulting residue was purified by NH-type silica gel columnchromatography (eluting solvent: n-hexane:ethyl acetate=9:1 to 1:1) togive the titled compound (1.4 g, 89%) as a colorless oil.

(3) Preparation of[1-(4-{4-[(2R)-2-methylpyrrolidin-1-yl]butoxy}phenyl)-1H-pyrazol-4-yl](morpholin-4-yl)methanone

The same procedure as shown in Example 6 was repeated to give the titledcompound, except that(2R)-1-[3-(4-iodophenoxy)propyl]-2-methylpyrrolidine was replaced by(2R)-1-[2-(4-iodophenoxy)ethyl]-2-methylpyrrolidine obtained in Example61-(2) (0.8 g).

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.10 (d, J=6.0 Hz, 3H), 1.38-1.47(m, 1H), 1.63-1.96 (m, 7H), 2.03-2.12 (m, 2H), 2.22-2.31 (m, 1H),2.79-2.88 (m, 1H), 3.14-3.21 (m, 1H), 3.71-3.81 (m, 8H), 4.02 (t, J=6.4Hz, 2H), 6.94-7.01 (m, 2H), 7.53-7.59 (m, 2H), 7.79 (s, 1H), 8.14 (s,1H)

MS (ESI/APCI Dual) (Positive) m/z; 413 (M+H)⁺

Example 62 Preparation of[1-(3-fluoro-4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl](morpholin-4-yl)methanone(1) Preparation of (2R)-1-(3-chloropropyl)-2-methylpyrrolidine

To a solution of (R)-2-methylpyrrolidine (18.0 g) and1-bromo-3-chloropropane (100.0 g) in acetone (360 mL), aqueous sodiumhydroxide (5 M, 50 mL) was added dropwise in an ice bath and the mixturewas heated to 80° C., at which it was stirred for 4 hours. The reactionmixture was extracted with diethyl ether, and the organic layer waswashed with brine, dried over anhydrous sodium sulfate and concentratedunder reduced pressure. The resulting residue was purified by NH-typesilica gel column chromatography (eluting solvent: n-hexane:ethylacetate=4:1 to 1:1) and silica gel column chromatography (elutingsolvent: chloroform:methanol=9:1) to give the titled compound (17.8 g,52%) as a yellow oil.

(2) Preparation of(2R)-1-[3-(4-bromo-2-fluorophenoxy)propyl]-2-methylpyrrolidine

To a suspension of 4-bromo-2-fluorophenol (0.57 g) and cesium carbonate(1.6 g) in acetonitrile (2.5 mL),(2R)-1-(3-chloropropyl)-2-methylpyrrolidine obtained in Example 62-(1)(0.40 g) was added and the mixture was heated to 100° C., at which itwas stirred for 4 hours. The reaction mixture was cooled to roomtemperature and filtered to remove insoluble materials, and the filtratewas concentrated under reduced pressure. The resulting residue waspurified by NH-type silica gel column chromatography (eluting solvent:n-hexane:ethyl acetate=10:1 to 3:1) to give the titled compound (0.73 g,94%) as a yellow oil.

(3) Preparation of[1-(3-fluoro-4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl](morpholin-4-yl)methanone

To a solution of(2R)-1-[3-(4-bromo-2-fluorophenoxy)propyl]-2-methylpyrrolidine obtainedin Example 62-(2) (0.72 g) and morpholin-4-yl(1H-pyrazol-4-yl)methanone(0.45 g) in N,N-dimethylformamide (3 mL), cesium carbonate (1.6 g),copper iodide (0.1 g) and (1R,2R)—N,N′-dimethylcyclohexane-1,2-diamine(0.36 mL) were added and the mixture was heated to 130° C., at which itwas stirred for 6 hours. The reaction mixture was cooled to roomtemperature and filtered to remove insoluble materials, and the filtratewas concentrated under reduced pressure. The resulting residue waspurified by silica gel column chromatography (eluting solvent:chloroform:methanol=11:1 to 3:1) and NH-type silica gel columnchromatography (eluting solvent: chloroform:methanol=10:0 to 100:1) togive the titled compound (0.34 g, 36%) as a colorless solid.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.09 (d, J=6.0 Hz, 3H), 1.37-1.47(m, 1H), 1.66-1.74 (m, 1H), 1.74-1.83 (m, 1H), 1.87-1.96 (m, 1H),1.99-2.08 (m, 2H), 2.08-2.16 (m, 1H), 2.18-2.27 (m, 1H), 2.27-2.35 (m,1H), 2.96-3.05 (m, 1H), 3.13-3.21 (m, 1H), 3.70-3.81 (m, 8H), 4.10-4.21(m, 2H), 7.02-7.09 (m, 1H), 7.32-7.37 (m, 1H), 7.45-7.51 (m, 1H),7.76-7.81 (m, 1H), 8.14 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 417 (M+H)⁺

Example 63 Preparation of[1-(2-methyl-4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl](morpholin-4-yl)methanone

The same procedure as shown in Example 62 was repeated to give thetitled compound, except that 4-bromo-2-fluorophenol was replaced by4-bromo-3-methylphenol.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.10 (d, J=6.0 Hz, 3H), 1.39-1.48(m, 1H), 1.67-1.74 (m, 1H), 1.75-1.84 (m, 1H), 1.89-1.97 (m, 1H),1.98-2.06 (m, 2H), 2.09-2.16 (m, 1H), 2.18 (s, 3H), 2.20-2.25 (m, 1H),2.26-2.35 (m, 1H), 2.95-3.04 (m, 1H), 3.15-3.22 (m, 1H), 3.72-3.82 (m,8H), 4.02-4.10 (m, 2H), 6.80 (dd, J=8.7, 2.8 Hz, 1H), 6.84 (d, J=2.8 Hz,1H), 7.21 (d, J=8.7 Hz, 1H), 7.81 (s, 1H), 7.86 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 413 (M+H)⁺

Example 64 Preparation of[1-(3-bromo-4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl](morpholin-4-yl)methanone

To a solution of4-{[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}morpholineobtained in Example 6 (0.500 g) in acetic acid (8.0 ml), bromine (0.200g) was added dropwise and stirred overnight at room temperature. Thereaction mixture was diluted with saturated aqueous sodium thiosulfateand concentrated under reduced pressure. The resulting residue wasdiluted with saturated aqueous sodium bicarbonate and extracted withchloroform. The organic layer was concentrated under reduced pressure,and the resulting residue was purified by NH-type silica gel columnchromatography (eluting solvent: n-hexane:ethyl acetate=1:1) to give thetitled compound (0.175 g) as a colorless solid.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.02-2.37 (m, 12H), 3.01-3.23 (m,2H), 3.71-3.79 (m, 8H), 4.10-4.17 (m, 2H), 6.97 (d, J=8.7 Hz, 1H), 7.54(dd, J=8.7, 2.8 Hz, 1H), 7.78 (s, 1H), 7.89 (d, J=2.8 Hz, 1H), 8.12 (s,1H)

MS (ESI/APCI Dual) (Positive) m/z; 477 (M+H)⁺

Example 65 Preparation of(2-hydroxymorpholin-4-yl)[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]methanone

To a solution of1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxylicacid bis-(2-hydroxyethyl)-amide obtained in Example 20 (1.0 g) inchloroform (8 mL), Dess-Martin reagent (1.1 g) was added and stirred atroom temperature for 16 hours. The reaction mixture was diluted withwater and extracted with chloroform. The organic layer was washed withbrine, dried over magnesium sulfate and concentrated under reducedpressure. The resulting residue was purified by silica gel columnchromatography (eluting solvent: chloroform:methanol=4:1) and furtherpurified by preparative TLC (1 mm thickness, developing solvent:chloroform:methanol=9:1) to give the titled compound (0.022 g) as acolorless amorphous substance.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.13 (d, J=6.0 Hz, 3H), 1.40-2.49(m, 10H), 2.97-3.07 (m, 1H), 3.23 (br.s, 1H), 3.49-4.20 (m, 7H), 5.07(t, J=3.2 Hz, 1H), 6.97 (d, J=8.7 Hz, 2H), 7.55 (d, J=8.7 Hz, 2H), 7.87(br.s, 1H), 8.19 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 415 (M+H)⁺

Example 66 Preparation ofN-(2-hydroxyethyl)-1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxamide

A mixture of1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxylicacid hydrochloride prepared in Example 2-(1) (1.00 g), 2-aminoethanol(0.400 g), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride(0.580 g), 1-hydroxybenzotriazole monohydrate (0.460 g) andN,N-dimethylformamide (10 mL) was stirred at room temperature for 4days. The reaction mixture was concentrated under reduced pressure, andthe resulting residue was purified by silica gel column chromatography(eluting solvent: chloroform:methanol=18:1) to give the titled compound(0.920 g) as a colorless solid.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.09 (d, J=6.0 Hz, 3H), 1.37-1.47(m, 1H), 2.21 (s, 8H), 2.93-3.25 (m, 2H), 3.56-3.64 (m, 2H), 3.79-3.86(m, 2H), 4.00-4.09 (m, 2H), 6.34-6.41 (m, 1H), 6.97 (d, J=9.2 Hz, 2H),7.55 (d, J=9.2 Hz, 2H), 7.91 (s, 1H), 8.28 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 373 (M+H)⁺

Example 67 Preparation of tert-butylN-(2-hydroxyethyl)-N-{[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}glycinate(1) Preparation ofN-{2-(tert-butyldimethylsilyloxy)ethyl}-1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxamide

A mixture ofN-(2-hydroxyethyl)-1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxamideprepared in Example 66 (0.500 g), tert-butylchlorodimethylsilane (0.303g), imidazole (0.273 g) and N,N-dimethylformamide (5.0 mL) was stirredovernight at room temperature. The reaction mixture was diluted withbrine and extracted with ethyl acetate. The organic layer was dried overmagnesium sulfate and concentrated under reduced pressure. The resultingresidue was purified by silica gel column chromatography (elutingsolvent: n-hexane:ethyl acetate=1:1) to give the titled compound (0.550g) as a colorless solid.

(2) Preparation of tert-butylN-{2-(tert-butyldimethylsilyloxy)ethyl}-N-{[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}glycinate

To a solution ofN-{2-(tert-butyldimethylsilyloxy)ethyl}-1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxamideprepared in Example 67-(1) (0.700 g) in N,N-dimethylformamide (5.0 mL),sodium hydride (55% in mineral oil, 0.058 g) was added and stirred atroom temperature for 20 minutes. To the reaction mixture, tert-butyl2-bromoacetate (0.281 g) was added and stirred for 30 minutes. Thereaction mixture was diluted with water and extracted with ethylacetate. The organic layer was dried over magnesium sulfate andconcentrated under reduced pressure. The resulting residue was purifiedby silica gel column chromatography (eluting solvent: n-hexane:ethylacetate=1:1) to give the titled compound (0.220 g) as a colorless oil.

(3) Preparation of tert-butylN-(2-hydroxyethyl)-N-{[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}glycinate

To a solution of tert-butylN-{2-(tert-butyldimethylsilyloxy)ethyl}-N-{[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}glycinateprepared in Example 67-(2) (0.220 g) in tetrahydrofuran (2.0 ml), asolution of tetrabutylammonium fluoride in tetrahydrofuran (1.0 M, 0.37ml) was added and stirred at room temperature for 30 minutes. Thereaction mixture was concentrated under reduced pressure, and theresulting residue was purified by silica gel column chromatography(eluting solvent: chloroform:methanol=18:1) to give the titled compound(0.180 g) as a colorless oil.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.09 (d, J=6.0 Hz, 3H), 1.37-2.38(m, 22H), 2.92-4.26 (m, 6H), 6.94-7.20 (m, 2H), 7.20-7.28 (m, 2H),7.49-7.60 (m, 1H), 7.71-8.42 (m, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 487 (M+H)⁺

Example 68 Preparation ofN-(2-hydroxyethyl)-N-{[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}glycine

To a solution of tert-butylN-(2-hydroxyethyl)-N-{[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}glycinateprepared in Example 67-(3) (0.218 g) in 1,4-dioxane (4.0 ml), a solutionof hydrochloric acid in ethyl acetate (4 M, 4.0 ml) was added andstirred at room temperature for 1 hour. The reaction mixture wasconcentrated under reduced pressure, and the resulting residue waspurified by octadecylsilyl (ODS) column chromatography (eluting solvent:acetonitrile:water=95:5) to give the titled compound (0.075 g) as acolorless amorphous substance.

1H NMR (600 MHz, METHANOL-d₃) δ ppm 1.37-1.50 (m, 3H), 1.70-1.81 (m,1H), 1.91-2.34 (m, 5H), 3.12-3.24 (m, 1H), 3.43-3.61 (m, 3H), 3.65-3.83(m, 5H), 4.12 (br. s., 4H), 7.03 (s, 2H), 7.60-7.66 (m, 2H), 7.88-8.04(m, 1H), 8.30-8.54 (m, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 431 (M+H)⁺

Example 69 Preparation ofN-[2-(2-hydroxyethoxy)ethyl]-1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazole-4-carboxamide

The same procedure as shown in Example 2-(2) was repeated to give thetitled compound, except that aqueous ammonia was replaced by2-(2-aminoethoxy)ethanol.

1H NMR (600 MHz, CHLOROFORM-d) δ ppm 1.03-1.13 (m, 3H), 1.37-2.34 (m,9H), 2.94-3.01 (m, 1H), 3.14-3.21 (m, 1H), 3.61-3.70 (m, 6H), 3.76-3.81(m, 2H), 4.01-4.09 (m, 2H), 6.39-6.44 (m, 1H), 6.97 (d, J=9.2 Hz, 2H),7.55 (d, J=9.2 Hz, 2H), 7.92 (s, 1H), 8.27 (s, 1H)

MS (ESI/APCI Dual) (Positive) m/z; 417 (M+H)⁺

Example 70 Preparation of4-{[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}morpholinemonohydrochloride

To a solution of4-{[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}morpholineobtained in Example 6-(2) (2.62 g) in ethyl acetate (18 mL), a solutionof hydrochloric acid in ethyl acetate (4 M, 2.46 mL) was added andstirred at room temperature for 30 minutes. The precipitated crystal wascollected by filtration to give a crude crystal (2.9 g). A suspension ofthe resulting crude crystal in ethanol (9 mL) was heated under reflux togive a solution, which was then filtered. After addition of ethanol (6mL), the filtrate was stirred for 30 minutes while cooling to roomtemperature. The mixture was further stirred in an ice bath for 1.5hours, and the precipitated crystal was collected by filtration anddried to give the titled compound (2.67 g) as a colorless powder.

1H NMR (600 MHz, DMSO-d₆) δ ppm 1.10-1.43 (m, 3H), 1.54-2.24 (m, 6H),2.99-3.23 (m, 2H), 3.33-3.52 (m, 2H), 3.47-3.89 (m, 9H), 4.02-4.19 (m,2H), 7.01-7.10 (m, 2H), 7.73-7.82 (m, 2H), 7.90 (s, 1H), 8.69 (s, 1H)

IR (KBr, cm⁻¹) 750, 827, 944, 996, 1048, 1119, 1251, 1439, 1518, 1552,1602, 2453, 2552, 2865

Elemental analysis for C₂₂H₃₀N₄O₃×1HCl

Calculated: C, 60.75%; H, 7.18%; N, 12.88%.

Found: C, 60.55%; H, 7.12%; N, 12.81%.

Melting point: 203.0° C.

Thermogravimetry: no change until the melting point (203.0° C.)

Example 71 Preparation of4-{[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}morpholinemonohydrochloride dihydrate

4-{[1-(4-{3-[(2R)-2-Methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}morpholinemonohydrochloride obtained in Example 70 was placed in a desiccatoradjusted to a humidity of 93% and stored for 2 days to give the titledcompound as a colorless powder.

Thermogravimetry: 7.32% reduction (corresponding to 2H₂O) at around 51°C.

Example 72 Preparation of4-{[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}morpholinemonohydrobromide

To a solution of4-{[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}morpholineobtained in Example 6-(2) (1.0 g) in ethanol (5 mL), a solution ofhydrobromic acid in ethanol (1.5 M, 2.0 mL) was added and stirred atroom temperature for 3 hours. The reaction mixture was concentratedunder reduced pressure, followed by addition of an ethanol:methanolsolution (95:5, 10 mL) to give a solution. This solution was stirred for3 hours while cooling in an ice bath. The precipitated solid wascollected by filtration and dried to give the titled compound (1.1 g) asa colorless powder.

1H NMR (600 MHz, DMSO-d₆) δ ppm 1.12-1.43 (m, 3H), 1.54-1.67 (m, 1H),1.84-2.28 (m, 5H), 3.08-3.18 (m, 2H), 3.41-3.51 (m, 2H), 3.57-3.73 (m,9H), 4.09-4.16 (m, 2H), 7.09 (d, J=9.2 Hz, 2H), 7.81 (d, J=9.2 Hz, 2H),7.91-7.96 (m, 1H), 8.72 (s, 1H), 9.25 (br. s., 1H)

IR (KBr, cm⁻¹) 751, 828, 944, 996, 1047, 1119, 1251, 1438, 1519, 1552,1604, 2519, 2603, 2866

Elemental analysis for C₂₂H₃₀N₄O₃×1HBr

Calculated: C, 55.12%; H, 6.52%; N, 11.69%.

Found: C, 54.99%; H, 6.44%; N, 11.67%.

Melting point: 202.0° C.

Test Example 1 H3 Receptor Binding Test

A membrane preparation of human H3 receptor-expressing CHO-K1 cells(Euroscreen, ES-392-M, 15 μg protein/200 μl), R(−)-α-methyl[³H]histamine(Amersham, TRK-1017, specific activity: 1.74 TBq/mmol, 2 nM) and a testdrug were reacted at room temperature for 1 hour. After completion ofthe reaction, the reaction mixture was subjected to suction filtrationthrough a 0.3% polyethyleneimine-treated glass filter (GF/C). The glassfilter was washed five times with 50 mM Tris-HCl washing solution (pH7.4) containing 5 mM EDTA. After washing, the glass filter was dried anda scintillator was added thereto, followed by measurement ofradioactivity on the filter using a liquid scintillation counter.

Binding of R(−)-α-methyl[³H]histamine in the presence of 10 μMR(−)-α-methylhistamine was defined as non-specific binding, and thedifference between total binding and non-specific binding ofR(−)-α-methyl[³H]histamine was defined as specific binding ofR(−)-α-methyl[³H]histamine. A fixed concentration (2 nM) ofR(−)-α-methyl[³H]histamine was reacted under the above conditions witheach test drug at various concentrations to obtain an inhibition curve.The inhibition curve was used to determine the concentration (IC₅₀) ofeach test drug required for 50% inhibition of R(−)-α-methyl[³H]histaminebinding. The IC₅₀ values of the compounds prepared in the examples areshown in Table 1.

TABLE 1 Example IC₅₀ (nM) 1 24.0 2 6.5 3 4.6 4 33.0 5 10.8 6 4.9 7 12.58 24.2 9 8.5 10 49.4 11 1.8 12 19.3 13 6.1 14 13.5 15 1.8 16 5.9 17 3.918 3.0 19 5.1 20 6.9 21 5.7 22 2.7 23 2.2 24 3.3 25 3.5 26 2.6 27 1.6 283.1 29 N.T. 30 3.3 31 5.1 32 8.3 33 N.T. 34 2.1 35 N.T. 36 4.0 37 2.1 380.9 39 3.5 40 4.4 41 2.1 42 1.7 43 1.0 44 0.8 45 1.1 46 1.4 47 1.5 484.1 49 3.1 50 31.9 51 13.7 52 6.0 53 6.1 54 4.1 55 5.2 56 2.8 57 50.7 588.7 59 1181 60 1560 61 39.2 62 8.7 63 20.7 64 10.0 65 5.9 66 N.T. 67N.T. 68 74.8 69 4.6 N.T. denotes “Not Tested.”

Test Example 2 [³⁵S]GTP-γ-S Binding Test

The same human H3 receptor membrane preparation as used in Test Example1 (7.5 μg protein/100 μl), 30 μM GDP, 100 μM R(−)-α-methylhistamine anda test compound were reacted at room temperature for 30 minutes. Aftercompletion of the reaction, [³⁵S]GTP-γ-S (0.2 nM) was added and reactedfor an additional 30 minutes. After completion of the reaction, thereaction mixture was subjected to suction filtration through a glassfilter (GF/C). The glass filter was washed three times with 20 mM HEPESwashing solution (pH 7.4) containing 100 mM sodium chloride and 1 mMmagnesium chloride. After washing, the glass filter was dried and ascintillator was added thereto, followed by measurement of radioactivityon the filter using a liquid scintillation counter.

Binding of [³⁵S]GTP-γ-S in the absence of R(−)-α-methylhistamine wasdefined as non-specific binding, and the difference between totalbinding in the presence of R(−)-α-methylhistamine and non-specificbinding was defined as specific binding of [³⁵S]GTP-γ-S. Fixedconcentrations of [³⁵S]GTP-γ-S (0.2 nM) and R(−)-α-methylhistamine (100μM) were reacted under the above conditions with each test drug atvarious concentrations to obtain an inhibition curve. The inhibitioncurve was used to determine the concentration (IC₅₀) of each test drugrequired for 50% inhibition of [³⁵S]GTP-γ-S binding. As a result, thecompound of Example 6 was found to have an IC₅₀ value of 3.1 nM, and thecompound of Example 30 was found to have an IC₅₀ value of 1.7 nM.

Test Example 3 [³H]diprenorphine Binding Test

Affinity for μ receptor was evaluated in a [³H]diprenorphine bindingtest by Cerep, Inc. The μ receptor preparation used was humanrecombinant μ receptor. The human recombinant μ receptor was incubatedwith [³H]diprenorphine (0.4 nM) at 22° C. for 120 minutes. Binding of[³H]diprenorphine in the presence of 1 μM naltrexone was defined asnon-specific binding, and the difference between total binding andnon-specific binding of [³H]diprenorphine was defined as specificbinding of [³H]diprenorphine.

Test Example 4 [³H]DADLE Binding Test

Affinity for δ receptor was evaluated in a [³H]DADLE binding test byCerep, Inc. The δ receptor preparation used was human recombinant δreceptor. The human recombinant δ receptor was incubated with [³H]DADLE(0.5 nM) at 22° C. for 120 minutes. Binding of [³H]DADLE in the presenceof 10 μM naltrexone was defined as non-specific binding, and thedifference between total binding and non-specific binding of [³H]DADLEwas defined as specific binding of [³H]DADLE.

Test Example 5 [³H](+)pentazocine Binding Test

Affinity for σ1 receptor was evaluated in a [³H](+)pentazocine bindingtest by Cerep, Inc. The σ1 receptor preparation used was the membrane ofJurkat cells. The Jurkat cell membrane was incubated with[³H](+)pentazocine (8 nM) at 22° C. for 120 minutes. Binding of[³H](+)pentazocine in the presence of 10 μM haloperidol was defined asnon-specific binding, and the difference between total bonding andnon-specific binding of [³H](+)pentazocine was defined as specificbinding of [³H](+)pentazocine.

Test Example 6 [³H]U69593 Binding Test

Affinity for K receptor was evaluated in a [³H]U69593 binding test byCerep, Inc. The K receptor preparation used was rat recombinant Kreceptor. The rat recombinant K receptor was incubated with [³H]U69593(1 nM) at 22° C. for 60 minutes. Binding of [³H]U69593 in the presenceof 10 μM naloxone was defined as non-specific binding, and thedifference between total binding and non-specific binding of [³H]U69593was defined as specific binding of [³H]U69593.

Table 2 shows the % inhibition of binding to each ligand caused by thecompound of Example 70 at 10 μM concentration in Test Examples 3 to 6.

TABLE 2 Opioid receptor binding test % Inhibition Receptor (10 μM) μ 3 δ−1 σ1 28 κ 17

Likewise, in Test Example 5, the compounds of Examples 54 and 55 at 10μM concentration were found to show 39% and 3% inhibition of ligandbinding, respectively.

Test Example 7 Metabolic Stability Test in Human Liver

Using human liver microsome (Xenotech, H0630), the in vitro metabolichalf-life was calculated. A reaction solution (300 μL) was prepared tocontain a test compound at 1 μM in 250 mM Na—K-phosphate buffer (pH 7.4)containing, at final concentrations, 2.4 mM MgCl₂, 1.5 mMglucose-6-phosphate (G-6-P), 0.18 U/mL glucose-6-phosphate dehydrogenase(G-6-P DH), 69 mM KCl, 0.16 mM (3-nicotinamide-adenine dinucleotidephosphate, oxidized form (NADP) and 1 mg microsomal protein/mL. Afterpre-incubation at 37° C. for 5 minutes, the NADP solution was added toinitiate the reaction. The incubation time was set to 0, 10, 20, 30, 45or 60 minutes. The reaction was stopped by addition of a CH₃CN:CH₃OH(1:1) solution in the same volume as that of the reaction solution. Thesample after the reaction was centrifuged at 3639×g at 4° C. for 10minutes, and the resulting supernatant was analyzed by LC/MS. Using thetime period during which linearity was observed, the metabolic half-lifewas calculated from the slope. As a result, the compound of Example 6was found to have a metabolic half-life of 180 minutes or longer.

Test Example 8 Social Recognition Test

This experiment was performed with Sprague-Dawley rats (male) accordingto the reported method (Shimazaki et al., European Journal ofPharmacology, 575, 94-97, 2007). Adult rats (9 weeks of age) were placedin a test cage and acclimated for 30 minutes. After 30 minutes, juvenilerats (4 weeks of age) were placed in the same test cage containing theadult rats, and allowed to stand for 5 minutes. During this 5 minutes,the time taken for the adult rats to show social behavior (sniffing,grooming, following) to the juvenile rats was measured (firstexploratory time). Then, the rats were removed from the test cage andreturned to their respective home cages. After 85 minutes, the adultrats were placed again in the test cage and acclimated for 30 minutes.The same juvenile rats as used in the first exploratory were placed inthe test cage, followed by measuring the time taken for the adult ratsto show social behavior (sniffing, grooming, following) to the juvenilerats during 5 minutes (second exploratory time). The social recognitionwas expressed as the ratio of second exploratory time/first exploratorytime. A test substance (the compound of Example 70) was orallyadministered to the adult rats immediately after their first socialbehavior. The results obtained are shown in Table 3.

TABLE 3 Ratio (second exploratory time/first exploratory time) Vehiclegroup 0.87 ± 0.05    Test substance 0.66 ± 0.06^(p<0.01) (10 mg/kg)group n = 18, statistical significance was analyzed by t-test

The test substance group showed a significant reduction in the ratio ofsecond exploratory time/first exploratory time when compared to thevehicle group, thus indicating that the test substance had an enhancingeffect on cognitive functions.

Test Example 9 Distribution Test in Rats

SD rats were used and orally administered once with the compound ofExample 70 at a dose of 3 mg/kg (2.75 mg/kg as a free form) to confirmthe tissue distribution of the compound in plasma, brain, liver, kidney,spleen, lung, heart, muscle, fat, testis, bone marrow and adrenal glandat 1, 2, 4, 8 and 24 hours after administration. For quantification,high performance liquid chromatography/tandem mass spectrometry(LC-MS/MS) was used. As a result, in the case of the compound of Example70, the unchanged form and major metabolites of its free form (i.e., thecompound of Example 6) were found to rapidly disappear from each organ.

Test Example 10 Cytotoxicity Test

Chinese hamster lung fibroblast-derived CHL/IU cells (DS PharmaBiomedical Co., Ltd., Japan) were seeded, and the medium was replaced onthe following day by another medium (MEM+2 mM L-Glutamine+10% CS (allpurchased from Invitrogen)) containing a test compound at variousconcentrations, followed by culture for an additional 48 hours. Using aCell counting kit-8 (Dojindo Laboratories, Japan), the survival rate ofthe cells was determined to obtain a curve whose horizontal axisrepresents the test compound concentration and whose vertical axisrepresents the survival rate. The curve thus obtained was used todetermine the concentration of the test compound at which the survivalrate was 50%. As a result, this concentration was 275, 441 and >640mmol/L for the compounds of Examples 56, 62 and 70, respectively.

INDUSTRIAL APPLICABILITY

The present invention enables the provision of pharmaceuticalpreparations which have a strong inhibitory effect against binding tohistamine H3 receptors and are useful for prevention or treatment ofhistamine H3 receptor-mediated disorders such as dementia, Alzheimer'sdisease, attention-deficit hyperactivity disorder, schizophrenia,epilepsy, central convulsion, eating disorders, obesity, diabetes,hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome,circadian rhythm disorder, depression, allergic rhinitis or otherdiseases. The present invention is expected to make a great contributionto the development of the pharmaceutical industry.

1. A phenylpyrazole derivative represented by formula (1) or a pharmaceutically acceptable salt thereof:

{wherein R¹ and R², which may be the same or different, each represent C₁-C₆ alkyl or C₃-C₈ cycloalkyl, or R¹ and R² are attached to each other together with their adjacent nitrogen atom to form a 4- to 7-membered saturated heterocyclic ring (wherein said saturated heterocyclic ring may be substituted with halogen or C₁-C₆ alkyl), n represents an integer of 0 to 2, T represents a hydrogen atom, halogen or C₁-C₆ alkyl, and R represents any one of formulae (II) to (VIII):

(wherein Z² represents —CH₂—, —O— or —NR¹¹—, q represents an integer of 0 to 1, s represents an integer of 0 to 2, R⁴ and R⁵, which may be the same or different, each represent a hydrogen atom, C₁-C₆ alkyl (wherein said C₁-C₆ alkyl may be substituted with halogen, C₃-C₈ cycloalkyl, C₁-C₆ alkoxy, hydroxy, hydroxy-C₁-C₆ alkoxy, C₂-C₇ alkoxycarbonyl or carboxy), C₃-C₈ cycloalkyl (wherein said C₃-C₈ cycloalkyl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy or hydroxy) or the formula —(CH₂)_(m)—Ar¹ (wherein Ar¹ represents aryl (wherein said aryl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano) or heteroaryl (wherein said heteroaryl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano), and m represents an integer of 0 to 2), R⁶ represents halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or oxo (provided that when Z² is —CH₂—, the hydrogen atom(s) may be replaced by R⁶), R⁷ represents a hydrogen atom or C₁-C₆ alkyl, R⁸ represents C₁-C₆ alkyl (wherein said C₁-C₆ alkyl may be substituted with halogen, C₃-C₈ cycloalkyl, C₁-C₆ alkoxy or hydroxy), C₃-C₈ cycloalkyl (wherein said C₃-C₈ cycloalkyl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy or hydroxy), C₁-C₆ alkoxy (wherein said C₁-C₆ alkoxy may be substituted with halogen, C₃-C₈ cycloalkyl, C₁-C₆ alkoxy or hydroxy) or the formula —(CH₂)₁-Ar² (wherein Ar² represents aryl (wherein said aryl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano) or heteroaryl (wherein said heteroaryl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano), and 1 represents an integer of 0 to 2), G represents —CO— or —SO₂—, R⁹ represents C₁-C₆ alkyl, C₃-C₈ cycloalkyl, C₁-C₆ alkoxy, aryl (wherein said aryl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano) or heteroaryl (wherein said heteroaryl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano), R¹⁰ represents C₁-C₆ alkyl, C₁-C₆ alkoxy, amino, C₁-C₆ alkylamino, C₂-C₁₂ dialkylamino, a 4- to 7-membered saturated heterocyclic ring (wherein said saturated heterocyclic ring may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano), aryl (wherein said aryl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano) or heteroaryl (wherein said heteroaryl may be substituted with halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, hydroxy or cyano), and R¹¹ represents hydrogen or C₁-C₆ alkyl)}.
 2. The phenylpyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein in formula (I), n is 1, T represents a hydrogen atom or halogen, and R¹ and R² are attached to each other together with their adjacent nitrogen atom to form a 5- to 6-membered saturated heterocyclic ring (wherein said saturated heterocyclic ring may be substituted with C₁-C₆ alkyl).
 3. The phenylpyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein in formula (I), R is formula (II).
 4. The phenylpyrazole derivative or pharmaceutically acceptable salt thereof according to claim 2, wherein in formula (I), R is formula (II).
 5. The phenylpyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein in formula (I), R is formula (III).
 6. The phenylpyrazole derivative or pharmaceutically acceptable salt thereof according to claim 2, wherein in formula (I), R is formula (III).
 7. The phenylpyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1, which is selected from the group consisting of: 1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxamide, 1-(4-{3-[(2S)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxamide, N-tert-butyl-1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazole-4-carboxamide, N-tert-butyl-1-{4-[3-(2,5-dimethylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazole-4-carboxamide, N-tert-butyl-1-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-1H-pyrazole-4-carboxamide, N-tert-butyl-1-{4-[3-(diethylamino)propoxy]phenyl}-1H-pyrazole-4-carboxamide, N-(4-fluorophenyl)-1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazole-4-carboxamide, N-(4-fluorophenyl)-1-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-1H-pyrazole-4-carboxamide, N-(4-methylphenyl)-1-{4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl}-1H-pyrazole-4-carboxamide, 1-{4-[3-(2-methylpyrrolidin-1-yl)-propoxy]-phenyl}-1H-pyrazole-4-carboxylic acid 4-fluorobenzylamide, 1-{4-[3-(2-methylpyrrolidin-1-yl)-propoxy]-phenyl}-1H-pyrazole-4-carboxylic acid dimethylamide, 1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxyl}phenyl)-1H-pyrazole-4-carboxylic acid bis-(2-hydroxyethyl)-amide, N-(2-hydroxyethyl)-1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxamide, tert-butyl N-(2-hydroxyethyl)-N-{[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}glycinate, N-(2-hydroxyethyl)-N-{[1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl]carbonyl}glycine, and N-[2-(2-hydroxyethoxy)ethyl]-1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazole-4-carboxamide.
 8. A method for treating dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, epilepsy, central convulsion, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression or allergic rhinitis, which comprises administering to a patient in need thereof an effective amount of the phenylpyrazole derivative according to claim 1 or the pharmaceutically acceptable salt. 